Document:

Exhibit 4.1

 

NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH
THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE
IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND,
ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS.

 

	SERIES B WARRANT NO. 2021-[______]	NUMBER
OF SHARES: [_______]
	DATE OF ISSUANCE: [__], 2021	(subject
to adjustment hereunder)
	EXPIRATION DATE: [__], 2024	 

 

SERIES B WARRANT TO PURCHASE SHARES

OF COMMON STOCK OF

IMMUNOME, INC.

 

This
Series B Warrant (the “Warrant”) is issued by Immunome, Inc., a Delaware corporation (the “Company”),
to [________] (including any successors or assigns, the “Holder”), and is subject to the terms and conditions set forth
below. The Warrant is being issued pursuant to a Warrant Agreement between the Company and American Stock Transfer & Trust
Company, LLC (the “Warrant Agent”). Capitalized terms used and not otherwise defined herein shall have the meanings
set forth in that certain Securities Purchase Agreement dated as of [__], 2021, among the Company and the purchasers signatory thereto
(the “Purchase Agreement”).

 

1.     EXERCISE
OF WARRANT.

 

(a)            Number
and Exercise Price of Warrant Shares; Expiration Date. Subject to the terms and conditions set forth herein, the Holder is entitled
to purchase from the Company at any time on or after [__], 20211
and on or prior to 5:00 p.m. (New York City time) on [__], 20242
(the “Expiration Date”) but not thereafter, up to [______] shares of the Company’s Common Stock, $0.0001 par
value per share (the “Common Stock”) (as adjusted from time to time pursuant to the provisions of this Warrant) (the
 “Warrant Shares”), at a purchase price of $45.00 per share (the “Exercise Price”).

 

 

1 Note to Draft: To be the Closing Date

2 Note to Draft: To be the 3 year anniversary of the Closing Date

 

    	 	1	 

     

    

 

(b)            Method
of Exercise. While this Warrant remains outstanding and exercisable in accordance with Section 1(a) above, the Holder may
exercise this Warrant in whole or in part in accordance with Section 5 by paying the Exercise Price by wire transfer to the Company
or cashier’s check drawn on a United States bank made payable to the order of the Company.

 

(c)            Call
Provision. Subject to the provisions of Section 5(c) and this Section 1(c), if, following the effectiveness of the
Registration Statement (the “Effective Date”), (i) the closing price per share of the Common Stock for any 20
trading days during any 30 trading day period (the “Measurement Period”) exceeds $55.00 (subject to adjustment for
forward and reverse stock splits, recapitalizations, stock dividends and the like after the date of issuance of this Warrant (the “Date
of Issuance”)) and (ii) the Holder is not in possession of any information that constitutes material non-public information
which was provided by (or on behalf of) the Company, then the Company may, within five (5) trading days of the end of such Measurement
Period, call for cancellation of up to 100% of the Warrant Shares represented by this Warrant for which an Exercise Notice (as defined
below) has not yet been delivered (such right, a “Call”). The consideration for the Call shall be equal to $0.0001
per Warrant Share. To exercise this right, the Company must deliver to the Holder an irrevocable written notice (a “Call Notice”),
indicating therein the portion of this Warrant to which such notice applies. If the conditions set forth in this Section 1(c) for
such Call are satisfied at any time from the date of the Call Notice through and including the Call Date (as defined below), then any
portion of this Warrant subject to the Call Notice that remains unexercised by the Call Date will be cancelled at 6:30 p.m. (New
York City time) on the fifth (5th) trading day after the date the Call Notice is received by the Holder (such date and time,
the “Call Date”). Any unexercised portion of this Warrant to which the Call Notice does not pertain will be unaffected
by such Call Notice. In furtherance thereof, the Company covenants and agrees that it will honor all Notices of Exercise with respect
to Warrant Shares subject to a Call Notice that are tendered through 6:30 p.m. (New York City time) on the Call Date. The parties
agree that any Exercise Notice delivered following a Call Notice which calls less than all of the Warrants for which the Holder has the
right to exercise shall first reduce to zero the number of Warrant Shares subject to such Call Notice prior to reducing the remaining
Warrant Shares available for purchase under this Warrant. Subject again to the provisions of this Section 1(c), the Company may deliver
subsequent Call Notices for any portion of this Warrant for which the Holder shall not have delivered an Exercise Notice. The Company’s
right to deliver a Call Notice and to exercise the Call Right thereunder is subject to the satisfaction of the following conditions from
the beginning of the Measurement Period through the Call Date, (1) the Registration Statement shall be effective as to all Warrant
Shares and the prospectus thereunder available for use by the Holder for the resale of all such Warrant Shares, and (2) the Common
Stock shall be listed or quoted for trading on the trading market on which the Common Stock is listed as reported by Bloomberg (as defined
below), and (3) there is a sufficient number of authorized shares of Common Stock for issuance of all Securities under the Transaction
Documents, and (4) the issuance of all Warrant Shares subject to a Call Notice shall not cause a breach of any provision of Section 5(c) herein.
The Company’s right to call the Warrants under this Section 1(c) shall be exercised ratably among the Holders based on
each Holder’s initial purchase of Warrants.

 

    	 	-2-	 

     

    

 

2.     CERTAIN
ADJUSTMENTS.

 

(a)            Adjustment
of Number of Warrant Shares and Exercise Price. The number and kind of Warrant Shares purchasable upon exercise of this Warrant and
the Exercise Price shall be subject to adjustment from time to time as follows:

 

(1)            Subdivisions,
Combinations and Other Issuances. If the Company shall at any time after the Date of Issuance but prior to the Expiration Date subdivide
its shares of capital stock of the same class as the Warrant Shares, by split-up or otherwise, or combine such shares of capital stock,
or issue additional shares of capital stock as a dividend with respect to any shares of such capital stock, the number of Warrant Shares
issuable on the exercise of this Warrant shall forthwith be proportionately increased in the case of a subdivision or stock dividend,
or proportionately decreased in the case of a combination. Appropriate adjustments shall also be made to the Exercise Price payable per
share, but the aggregate Exercise Price payable for the total number of Warrant Shares purchasable under this Warrant (as adjusted) shall
remain the same. Any adjustment under this Section 2(a)(1) shall become effective at the close of business on the date the subdivision
or combination becomes effective, or as of the record date of such dividend, or in the event that no record date is fixed, upon the making
of such dividend.

 

(2)            Reorganizations.
In case of any reclassification, capital reorganization or change in the capital stock of the Company (other than as a result of a subdivision,
combination or stock dividend provided for in Section 2(a)(1) above) that occurs after the Date of Issuance, then, as a condition
of such reclassification, reorganization or change, lawful provision shall be made, and duly executed documents evidencing the same from
the Company or its successor shall be delivered to the Holder, so that the Holder shall thereafter have the right at any time prior to
the expiration of this Warrant to purchase, at a total price equal to that payable upon the exercise of this Warrant, the kind and amount
of shares of stock and/or other securities or property (including, if applicable, cash) receivable in connection with such reclassification,
reorganization or change by a holder of the same number and type of securities as were purchasable as Warrant Shares by the Holder immediately
prior to such reclassification, reorganization or change. In any such case, appropriate provisions shall be made with respect to the rights
and interest of the Holder so that the provisions hereof shall thereafter be applicable with respect to any shares of stock or other securities
or property deliverable upon exercise hereof, and appropriate adjustments shall be made to the Exercise Price payable hereunder, provided
the aggregate Exercise Price shall remain the same (and, for the avoidance of doubt, this Warrant shall be exclusively exercisable for
such shares of stock and/or other securities or property from and after the consummation of such reclassification or other change in the
capital stock of the Company).

 

    	 	-3-	 

     

    

 

(3)            Rights
Upon Distribution of Assets. If the Company shall declare or make any dividend, other distribution of its assets (or rights to acquire
its assets) or evidences of its indebtedness to holders of shares of Common Stock generally (which dividend or other distribution has
not already been given to the Holder with respect to the Warrant Shares), by way of return of capital or otherwise not addressed by this
Section 2 above (including, without limitation, any distribution of cash, stock or other securities, property or options by way of
a dividend, spin off, subdivision, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”),
at any time after the issuance of this Warrant and prior to the Expiration Date, then, in each such case the Holder shall be entitled
(subject to the following proviso) to participate in such Distribution to the same extent that the Holder would have participated therein
if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations
or restrictions on exercise of this Warrant, including, without limitation, the Beneficial Ownership Limitation) immediately before the
date on which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the participation in such Distribution; provided, however, that the Holder shall
only be permitted to take delivery of such Distribution if and to the extent the Holder exercises some or all of the Warrant (the portion
of delivery of the Distribution shall be based on the pro rata portion of the Warrant Shares issuable upon the portion of the Warrant
exercised as compared to the maximum number of Warrant Shares issuable upon complete exercise of the Warrant (without regard to any limitations
or restrictions on exercise of this Warrant, including, without limitation, the Beneficial Ownership Limitation)), provided that, to the
extent that the Warrant has not been partially or completely exercised at the time of such Distribution, such portion of the Distribution
shall be held in abeyance for the benefit of the Holder until the Holder has exercised the Warrant, at which time the Company shall issue
to the Holder the pro-rata portion of such Distribution equivalent to that portion of this Warrant then exercised. Notwithstanding
anything to the contrary contained herein, to the extent that the Holder’s right to participate in any such Distribution would result
in the Holder and its affiliates exceeding the Beneficial Ownership Limitation, if applicable pursuant to Section 5(c) herein,
then the Holder shall not be entitled to participate in such Distribution to the extent of the Beneficial Ownership Limitation (and shall
not be entitled to beneficial ownership of such shares of Common Stock as a result of such Distribution (and beneficial ownership) to
the extent of any such excess) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such
time or times, if ever, as its right thereto would not result in the Holder and its affiliates exceeding the Beneficial Ownership Limitation,
at which time or times the Holder shall be granted such Distribution (and any Distributions declared or made on such initial Distribution
or on any subsequent Distribution held similarly in abeyance) to the same extent as if there had been no such limitation).

 

(b)           Notice
of Adjustment. When any adjustment is required to be made in the number or kind of shares purchasable upon exercise of the Warrant,
or in the Exercise Price, the Company shall promptly notify the Holder of such event and of the number of Warrant Shares or other securities
or property thereafter purchasable upon exercise of this Warrant.

 

(c)            Calculations.
No adjustment in the Exercise Price shall be required unless such adjustment would require an increase or decrease of at least $0.01 in
such price; provided, however, that any adjustment which by reason of this Section 2(c) is not required to be
made shall be carried forward and taken into account in any subsequent adjustments under this Section 2. All calculations under this
Section 2 shall be made by the Company in good faith and shall be made to the nearest cent or to the nearest one hundredth of a share,
as applicable. No adjustment need be made for a change in the par value or no par value of the Company’s Common Stock.

 

    	 	-4-	 

     

    

 

(d)           Treatment
of Warrant upon a Change of Control.

 

(1)            If,
at any time while this Warrant is outstanding, there is a Change of Control (as defined below), then the Holder shall have the right
at any time prior to the expiration of this Warrant to receive, upon exercise of this Warrant, the same amount and kind of securities,
cash or property as it would have been entitled to receive upon the occurrence of such Change of Control if it had been, immediately
prior to such Change of Control, the holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant (the
 “Alternate Consideration”). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately
adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of
Common Stock in such Change of Control, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable
manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given
any choice as to the securities, cash or property to be received in a Change of Control, then the Holder shall be given the same choice
as to the Alternate Consideration it receives upon any exercise of this Warrant following such Change of Control. Any successor to the
Company or surviving entity in such Change of Control shall issue to the Holder a new warrant substantially in the form of this Warrant
and consistent with the foregoing provisions and evidencing the Holder’s right to purchase the Alternate Consideration for the
aggregate Exercise Price upon exercise thereof.

 

(2)            Notice
of a Change of Control. The Company shall provide written notice to the Holder of a Change of Control reasonably promptly after public
announcement thereof (and, in any event, not less than five (5) trading days prior to the consummation of such Change of Control)
and such notice shall include (i) the projected date of consummation of the Change of Control to the extent known at the time such
notice is delivered and (ii) the expected consideration to be received by the Company’s stockholders in such Change of Control.

 

(3)            As
used in this Warrant, a “Change of Control” shall mean (i) a merger or consolidation of the Company with another
entity, in which the Company is not the survivor or the stockholders of the Company immediately prior to such merger or consolidation
do not own, directly or indirectly, at least 50% of the voting securities of the surviving entity, (ii) the sale, assignment, transfer,
conveyance or other disposal of all or substantially all of the assets or all or at least 50% of the outstanding voting securities of
the Company, (iii) a purchase, tender or exchange offer accepted by the holders of a majority of the outstanding voting shares of
capital stock of the Company directly or indirectly, in one or more related transactions, or (iv) a “person” or “group”
(as these terms are used for purposes of Section 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the
 “Exchange Act”)) is or shall become the “beneficial owner” (as defined in Rule 13d-3 under the Exchange
Act), directly or indirectly, of at least a majority of the outstanding shares of Common Stock of the Company through a stock purchase
agreement or other business combination (including, without limitation, a reorganization, reclassification, spin off or scheme of arrangement)
with another person.

 

    	 	-5-	 

     

    

 

3.     NO
STOCKHOLDER RIGHTS. Until the exercise of this Warrant, the Holder shall not have, nor be entitled to exercise, any rights as a stockholder
of the Company (including without limitation the right to notification of stockholder meetings or the right to receive any notice or
other communication concerning the business and affairs of the Company), except as provided in Section 2 above.

 

4.     COVENANT
TO PERFORM; NON-CIRCUMVENTION. The Company hereby covenants and agrees that the Company will at all times in good faith carry out all
the provisions of this Warrant and will not, by amendment of its certificate of incorporation, bylaws or other organizational documents
or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant. Without limiting
the generality of the foregoing, the Company (i) shall not increase the par value of any shares of Common Stock receivable upon the
exercise of this Warrant above the Exercise Price then in effect, (ii) shall take such actions as shall be necessary in order that
the Company may validly and legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant, and (iii) shall,
so long as this Warrant is outstanding, take action necessary to reserve and keep available out of its authorized and unissued shares
of Common Stock, solely for the purpose of effecting the exercise of this Warrant, 100% of the number of shares of Common Stock issuable
upon exercise of this Warrant then outstanding.

 

    	 	-6-	 

     

    

 

5.     MECHANICS
OF EXERCISE. (a)       Delivery of Warrant Shares Upon Exercise.
This Warrant may be exercised by the Holder hereof upon the delivery of a Notice of Exercise (the “Exercise Notice”)
attached hereto as Exhibit A properly completed and duly executed by the Holder hereof, at the office of the Warrant Agent
designated for such purpose together with this Warrant and payment in full of the Exercise Price then in effect with respect to the number
of Warrant Shares as to which the Warrant is being exercised. This Warrant shall be deemed to have been exercised immediately prior to
the close of business on the date of its surrender for exercise as provided above, and the person entitled to receive the Warrant Shares
issuable upon such exercise shall be treated for all purposes as the holder of such shares of record as of the close of business on such
date. Notwithstanding anything herein to the contrary (although the Holder may surrender the Warrant to, and receive a replacement Warrant
from, the Warrant Agent), the Holder shall not be required to physically surrender this Warrant to the Warrant Agent until the Holder
has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall
surrender this Warrant to the Warrant Agent for cancellation within three (3) trading days of the date the final Exercise Notice
is delivered to the Warrant Agent. Execution and delivery of the Exercise Notice with respect to less than all of the Warrant Shares available
hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable
number of Warrant Shares purchased. On or before the second (2nd) trading day following the date on which the Warrant Agent
has received each of the Exercise Notice, this Warrant and the aggregate Exercise Price, the Warrant Agent shall transmit by facsimile
an acknowledgment of confirmation of receipt of the Exercise Notice to the Company’s transfer agent (“Transfer Agent”).
The Company shall deliver any objection to the Exercise Notice on or before the second trading day following the date on which the Company
has received the Exercise Notice. On or before the second (2nd) trading day following the date on which the Warrant Agent has
received the Exercise Notice and the aggregate Exercise Price (the “Share Delivery Date”), the Warrant Agent shall
(X) provided that the Transfer Agent is participating in The Depository Trust Company (“DTC”) Fast Automated Securities
Transfer Program and there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant
Shares by the Holder, credit such aggregate number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the
Holder’s or its designee’s balance account with DTC through its Deposit Withdrawal Agent Commission system, or (Y) if
the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, or there is not an effective registration
statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder, issue and dispatch by first
class mail, postage prepaid, to the address as specified in the Exercise Notice, a book-entry position evidencing the number of shares
of Common Stock to which the Holder is entitled pursuant to such exercise. Upon delivery of the Exercise Notice and the payment of the
aggregate Exercise Price, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares
with respect to which this Warrant has been exercised, irrespective of the date such Warrant Shares are credited to the Holder’s
DTC account or the date of delivery of the book-entry position evidencing such Warrant Shares, as the case may be. The Company shall pay
any and all taxes (other than taxes based upon the income of the Holder) which may be payable with respect to the issuance and delivery
of Warrant Shares upon exercise of this Warrant; provided, that the Company shall not be required to pay any tax that may be payable
in respect of any transfer involved in the issue and delivery of shares of Common Stock in any name other than that of the Holder, in
either case with respect to any income or transfer tax due by the Holder with respect to such shares of Common Stock issued upon exercise
of this Warrant. The Warrant Agent shall not have any duty or obligation to take any action under any section of this Agreement that requires
the payment of taxes and/or charges unless and until it is satisfied that all such payments have been made.

 

    	 	-7-	 

     

    

 

(b)           Company’s
Failure to Timely Deliver Securities. If the Company shall fail for any reason or for no reason to issue to the Holder by the Share
Delivery Date in compliance with the terms of this Section 5, a book entry position for the number of shares of Common Stock to which
the Holder is entitled and register such shares of Common Stock on the Company’s share register or to credit the Holder’s
balance account with DTC for such number of shares of Common Stock to which the Holder is entitled upon the Holder’s exercise of
this Warrant, and if on or after such trading day the Holder purchases (in an open market transaction or otherwise, provided such purchases
(other than in an open market transaction) shall be made in a commercially reasonable manner at prevailing market prices) shares of Common
Stock to deliver in satisfaction of a sale by the Holder of shares of Common Stock issuable upon such exercise that the Holder anticipated
receiving from the Company, then the Company shall, within three (3) trading days after the Holder’s request and in the Holder’s
discretion, either (i) pay cash to the Holder in an amount equal to the Holder’s total purchase price (including commercially
reasonable brokerage commissions, if any) for the shares of Common Stock so purchased (the “Buy-In Price”), at which
point the Company’s obligation to deliver such evidence of book entry position (and to issue such Warrant Shares) shall terminate,
or (ii)  pay cash to the Holder in an amount equal to the excess (if any) of the Buy-In Price over the product of (A) such number
of shares of Common Stock, times (B) the price at which the sell order giving rise to such purchase obligation was executed (assuming
such sale was executed on commercially reasonable terms at prevailing market prices, which shall be presumed in the case of any open market
transaction) and, at the option of the holder, either (x) promptly honor its obligation to deliver to the Holder evidence of book
entry position representing such Warrant Shares or (y) reinstate the portion of the Warrant and equivalent number of Warrant Shares
for which such exercise was not honored (in which case such exercise shall be deemed rescinded). The
Warrant Agent shall have no responsibility for any amounts that may be payable or paid to any Holder, person or entity under this Warrant
for any such failure by the Company (or the Warrant Agent on the Company’s behalf) and the Company shall indemnify and hold harmless
the Warrant Agent against all claims made against the Warrant Agent for any such failure.

 

    	 	-8-	 

     

    

 

(c)            Holder’s
Exercise Limitation. Notwithstanding anything to the contrary contained in this Warrant,
this Warrant shall not be exercisable by the Holder pursuant to Section 1 or otherwise, to the extent (but only to the extent) that
after giving effect to such issuance after exercise as set forth on the applicable Exercise Notice, the Holder (together with the Holder’s
affiliates (as such term is defined pursuant to the Exchange Act), and any other persons acting as a group together with the Holder or
any of the Holder’s affiliates (such person, “Attribution Parties”)), would beneficially own in excess of [4.99/9.99]%
of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable
upon exercise of this Warrant (the “Beneficial Ownership Limitation”); provided, that notwithstanding anything
herein to the contrary, this limitation on exercise shall not be applicable to any person that beneficially owns 10.0% or more of the
Company’s outstanding Common Stock immediately prior to the exercise of this Warrant, but without giving effect to any shares of
Common Stock underlying this Warrant. Notwithstanding the forgoing, the Holder shall have the right to increase or decrease the Beneficial
Ownership Limitation (to an amount not to exceed 19.99% of the number of shares of Common Stock outstanding immediately after giving effect
to the issuance of shares of Common Stock issuable upon exercise of this Warrant, with any increase to be effective only upon the Holder
providing the Company with prior written notice of such increase, which shall be effective 61 days after delivery of such notice to the
Company. To the extent the above limitation applies, the determination of whether this Warrant shall be exercisable (vis-à-vis
other convertible, exercisable or exchangeable securities owned by the Holder or any of its Attribution Parties) and of which such securities
shall be exercisable (as among all such securities owned by the Holder or any of its Attribution Parties) shall, subject to such Beneficial
Ownership Limitation, be determined by the Holder, and the Company shall have no responsibility for determining the accuracy of the Holder’s
determination. No prior inability to exercise this Warrant pursuant to this paragraph shall have any effect on the applicability of the
provisions of this paragraph with respect to any subsequent determination of exercisability. For purposes of the calculation of the Beneficial
Ownership Limitation, the aggregate number of shares of Common Stock beneficially owned by the Holder and its Attribution Parties shall
include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being
made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised
portion of this Warrant beneficially owned by the Holder or any of its Attribution Parties and (ii) exercise or conversion of the
unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other convertible notes
or convertible preferred stock or warrants) subject to a limitation on conversion or exercise analogous to the limitation contained herein
beneficially owned by the Holder or any of its Attribution Parties. Except as set forth in the preceding sentence, for purposes of this
section, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and
regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation
is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be
filed in accordance therewith. In addition, a determination as to any group status as contemplated above shall be determined in accordance
with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 5(c),
in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock
as reflected in (A) the Company’s most recent periodic or annual report filed with the Securities and Exchange Commission,
as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company
or the Company’s transfer agent setting forth the number of shares of Common Stock outstanding. In any case, the number of outstanding
shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this
Warrant, by the Holder or its Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported.
The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of
this Section 5(c) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended
Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such
limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. Upon the reasonable written
request of the Holder, the Company shall within three (3) trading days confirm orally or in writing to the Holder the number of shares
of Common Stock then outstanding, including by virtue of any prior conversion or exercise of convertible or exercisable securities into
Common Stock, including, without limitation, pursuant to this Warrant or securities issued pursuant to the Purchase Agreement.

 

6.     CERTIFICATE
OF ADJUSTMENT. Whenever the Exercise Price or number or type of securities issuable upon exercise of this Warrant is adjusted, as herein
provided, the Company shall, at its expense, promptly deliver to the Holder and the Warrant Agent a certificate of an officer of the Company
setting forth the nature of such adjustment and showing in detail the facts upon which such adjustment is based. The Warrant Agent shall
be fully protected in relying on such a certificate and shall have not be deemed to have any knowledge of the occurrence of an adjustment
unless and until it has received such a certificate. In no event shall the Warrant Agent have any obligation to calculate any of the adjustments,
all such calculations being the responsibility of the Company.

 

    	 	-9-	 

     

    

 

7.     NOTICES.
In the event of:

 

(a)           any
taking by the Company of a record of the holders of any class of securities for the purpose of determining the holders thereof who are
entitled to receive any dividend (other than a cash dividend payable out of earned surplus of the Company) or other distribution, or any
right to subscribe for, purchase or otherwise acquire any shares of stock of any class or any other securities or property, or to receive
any other right; or

 

(b)           any
voluntary or involuntary dissolution, liquidation or winding-up of the Company, then and in each such event the Company will promptly
mail or cause to be delivered to the Warrant Agent and Holder (or a permitted transferee) a notice specifying (i) the date on which
any such record is to be taken for the purpose of such dividend, distribution or right, and stating the amount and character of such dividend,
distribution or right, and (ii) the date on which any such dissolution, liquidation or winding-up is to take place, and the time,
if any, as of which the holders of record of Common Stock (or other securities) shall be entitled to exchange their shares of Common Stock
(or other securities) for securities or other property deliverable upon such dissolution, liquidation or winding-up. Such notice shall
be delivered at least twenty (20) days prior to the date therein specified.

 

(c)           Whenever
any other notice is required to be given under this Warrant, unless otherwise provided herein, the Company shall provide prompt written
notice of all actions taken pursuant to this Warrant, including in reasonable detail a description of such action and the reason therefor.

 

8.     REPLACEMENT
OF WARRANTS. On receipt of evidence reasonably satisfactory to the Company and Warrant Agent of the loss, theft, destruction or mutilation
of this Warrant and, in the case of any such loss, theft or destruction of this Warrant, on delivery of an indemnity agreement reasonably
satisfactory in form and amount to the Company and Warrant Agent or, in the case of any such mutilation, on surrender and cancellation
of such Warrant, the Company at its expense will execute and deliver, in lieu thereof, a new Warrant of like tenor.

 

9.     ISSUANCE
OF NEW WARRANTS. Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant, such new Warrant (i) shall
be of like tenor with this Warrant, (ii) shall represent, as indicated on the face of such new Warrant, the right to purchase the
Warrant Shares then underlying this Warrant (or in the case of a new Warrant being issued pursuant to Sections 8 or 9, the Warrant Shares
designated by the Holder which, when added to the number of shares of Common Stock underlying the other new Warrants issued in connection
with such issuance, does not exceed the number of Warrant Shares then underlying this Warrant), (iii) shall have an issuance date,
as indicated on the face of such new Warrant which is the same as the Date of Issuance, and (iv) shall have the same rights and conditions
as this Warrant.

 

    	 	-10-	 

     

    

 

10.   NO
FRACTIONAL SHARES. No fractional Warrant Shares or scrip representing fractional shares will be issued upon exercise of this Warrant.
In lieu of any fractional shares which would otherwise be issuable, the Company shall pay cash equal to the product of such fraction multiplied
by the Fair Market Value of one Warrant Share. For purposes of this Section 10, the “Fair Market Value” of one Warrant
Share shall mean (x) the last reported sale price and, if there are no sales, the last reported bid price, of the Common Stock on
the last trading day prior to the date of exercise on the trading market on which the Common Stock is listed as reported by Bloomberg
Financial Markets (or a comparable reporting service of national reputation selected by the Company and reasonably acceptable to the Holder
if Bloomberg Financial Markets is not then reporting sales prices of the Common Stock) (collectively, “Bloomberg”),
or (y) if the foregoing does not apply, the last sales price of such security in the over-the-counter market on the pink sheets by
Pink Sheets LLC (formerly the National Quotation Bureau, Inc.) (the “pink sheets”) or bulletin board for such security
as reported by Bloomberg, or if no sales price is so reported, the last bid price of the Common Stock as reported by Bloomberg or (z) if
the fair market value cannot be calculated on any of the foregoing bases, the fair market value determined by the Company’s Board
of Directors in good faith.

 

11.   AMENDMENT
AND WAIVER. Except as otherwise provided herein, the provisions of this Warrant may be amended and the Company may take any action herein
prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent of
the Holder.

 

12.   TRADING
DAYS. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall be other
than a day on which the Common Stock is traded (which for the avoidance of doubt includes a Saturday, Sunday or a legal U.S. holiday)
on the Nasdaq Global Select Market, or, if the Nasdaq Global Select Market is not the principal trading market for the Common Stock or
other such securities, as applicable, then on the principal securities exchange or securities market on which the Common Stock is then
traded, then such action may be taken or such right may be exercised on the next succeeding day on which the Common Stock is so traded.

 

13.   TRANSFERS;
EXCHANGES.

 

(a)            Subject
to compliance with applicable transfer restrictions under the Purchase Agreement and applicable federal and state securities laws, this
Warrant may be transferred by the Holder with respect to all of the Warrant Shares purchasable hereunder. For a transfer of this Warrant
as an entirety by Holder, upon surrender of this Warrant to the Warrant Agent, together with the Notice of Assignment in the form attached
hereto as Exhibit B properly completed and duly executed by the Holder, the Company shall issue a new Warrant of the same
denomination to the assignee. Upon surrender of this Warrant to the Warrant Agent, together with the Notice of Assignment in the form
attached hereto as Exhibit B properly completed and duly executed by the Holder, for transfer of this Warrant with respect
to a portion of the Warrant Shares purchasable hereunder, the Company will forthwith issue and deliver upon the order of the Holder a
new Warrant (in accordance with Section 9), registered as the Holder may request, representing the right to purchase the number of
Warrant Shares being transferred by the Holder and, if less than the total number of Warrant Shares then underlying this Warrant is being
transferred, a new Warrant (in accordance with Section 9) to the Holder representing the right to purchase the number of Warrant
Shares not being transferred.

 

    	 	-11-	 

     

    

 

(b)           This
Warrant is exchangeable, without expense, at the option of the Holder, upon presentation and surrender hereof to the Warrant Agent for
other warrants of different denominations entitling the holder thereof to purchase in the aggregate the same number of shares of Common
Stock purchasable hereunder. This Warrant may be combined with other warrants that carry the same rights upon presentation hereof at the
office of the Warrant Agent designated for such purpose together with a written notice specifying the denominations in which new warrants
are to be issued to the Holder and signed by the Holder hereof. The term “Warrants” as used herein includes any warrants into
which this Warrant may be divided or exchanged.

 

(c)            If,
at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be
either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable state securities
or blue sky laws or (ii) eligible for resale pursuant to Rule 144, the Company may require, as a condition of allowing such
transfer, that the Holder or transferee of this Warrant, as the case may be, provide to the Company an opinion of counsel selected by
the Holder and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company,
to the effect that such transfer does not require registration of such transferred Warrant under the Securities Act.

 

(d)           The
Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire
the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant
Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered
or exempted under the Securities Act.

 

14.   GOVERNING
LAW; VENUE. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and
construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of
law thereof. With respect to any disputes arising out of or related to this Warrant, the parties consent to the exclusive jurisdiction
of, and venue in, the state courts in the State of New York (or in the event of exclusive federal jurisdiction, the courts of the District
of New York). Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit,
action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such
party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE
LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS WARRANT OR THE TRANSACTIONS CONTEMPLATED
HEREBY.

 

    	 	-12-	 

     

    

 

15.   DISPUTE
RESOLUTION. In the case of a dispute as to the determination of the Exercise Price, the arithmetic calculation of the Warrant Shares or
under Sections 2 or 6, the disputing party shall submit the disputed determinations or arithmetic calculations to the other party. If
the Holder and the Company are unable to agree upon such determination or calculation of the Exercise Price or the Warrant Shares within
three (3) trading days of such disputed determination or arithmetic calculation being submitted to the non-disputing party, then
the Company shall, within two (2) trading days submit the dispute to an independent, reputable accountant. The Company shall cause,
at the expense of the prevailing party, the accountant to perform the determinations or calculations and notify the Company and the Holder
of the results no later than ten (10) trading days from the time it receives the disputed determinations or calculations. Such accountant’s
determination or calculation shall be binding upon all parties absent demonstrable error.

 

16.   REMEDIES,
OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF. The remedies provided in this Warrant shall be cumulative and in addition to all other
remedies available under this Warrant, at law or in equity (including a decree of specific performance and/or other injunctive relief),
and nothing herein shall limit the right of the Holder to pursue actual damages for any failure by the Company to comply with the terms
of this Warrant.

 

17.   CONSTRUCTION;
HEADINGS. This Warrant shall be deemed to be jointly drafted by the Company and the Holder and shall not be construed against any person
as the drafter hereof. The headings of this Warrant are for convenience of reference and shall not form part of, or affect the interpretation
of, this Warrant.

 

18.   SUCCESSORS
AND ASSIGNS. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit
of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of the Holder. The
provisions of this Warrant are intended to be for and the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.

 

19.   RESTRICTIONS.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, must comply with the applicable
restrictions upon resale imposed by (a) state and federal securities laws and (b) the Purchase Agreement.

 

20.   MISCELLANEOUS.
All notices, requests, consents and other communications hereunder shall be in writing, shall be sent by confirmed electronic mail, or
mailed by first-class registered or certified airmail, or nationally recognized overnight express courier, postage prepaid, and shall
be deemed given when so sent in the case of electronic mail transmission, or when so received in the case of mail or courier, and addressed
as follows: (a) if to the Company, at 665 Stockton Drive, Suite 300, Exton, PA 19341, Attention: Chief Financial Officer (Email:
croche@immunome.com); with a copy (which shall not constitute notice) to Sandra G. Stoneman, Chief Legal Officer and General Counsel,
665 Stockton Drive, Suite 300, Exton, PA 19341, Email: sstoneman@immunome.com and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo,
P.C., 666 Third Avenue, New York, NY 10017 Attention: Kenneth R. Koch, Email: krkoch@mintz.com and (b) if to the Holder, at such
address or addresses (including copies to counsel) as may have been furnished by the Holder to the Company in writing. The invalidity
or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provisions.

 

[Signature Page Follows]

 

    	 	-13-	 

     

    

 

IN
WITNESS WHEREOF, this Common Stock Purchase Warrant is issued effective as of the date first set forth above.

 

	 	IMMUNOME, INC.
	 	 	 
	 	By:	 
	 	Name:	Purnanand Sarma, PhD
	 	Title:	CEO & President

 

     

     

    

 

EXHIBIT A

 

NOTICE OF INTENT TO EXERCISE

(To be signed only upon exercise of Warrant)

 

To: Immunome, Inc.

 

The undersigned, the Holder
of the attached Warrant, hereby irrevocably elects to exercise the purchase right represented by such Warrant for, and to purchase thereunder,
__________________________ shares of Common Stock of Immunome, Inc., a Delaware corporation (the “Company”), and
herewith makes payment of USD ___________________________ thereof.

 

The undersigned requests that the book entry
position evidencing the shares to be acquired pursuant to such exercise be issued in the name of, and delivered to
__________________________________________, whose address is
_____________________________________________________ _______________________________________________.

 

By
its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise evidenced
hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section 13(d) of
the Securities Exchange Act of 1934, as amended) permitted to be owned under Section 5(c) of the Warrant to which this notice
relates.

 

By its signature below the
undersigned hereby represents and warrants that it is an “accredited investor” as defined in Rule 501(a) of Regulation
D promulgated under the Securities Act of 1933, as amended, and agrees to be bound by the terms and conditions of the attached Warrant
as of the date hereof, including Section 7 thereof.

 

	DATED:	 	 

 

	(Signature must conform in all

 respects to name of
the Holder

 as specified on the face of the Warrant)	 

 

 

Name of Investing Entity:______________________________________________

 

Signature
of Authorized Signatory of Investing Entity: __________________________________

 

Name of Authorized Signatory:
______________________________________________

 

Title of Authorized Signatory:
______________________________________________

 

     

     

    

 

EXHIBIT B

 

NOTICE OF ASSIGNMENT FORM

 

FOR VALUE RECEIVED, [Holder
Name] (the “Assignor”) hereby sells, assigns and transfers all of the rights of the undersigned Assignor under the
attached Warrant with respect to the number of shares of common stock of Immunome, Inc., a Delaware corporation (the “Company”),
covered thereby set forth below, to the following “Assignee” and, in connection with such transfer, represents and
warrants to the Company that the transfer is in compliance with Section 7 of the Warrant, applicable transfer restrictions under
the Purchase Agreement (as defined in the Warrant) and applicable federal and state securities laws:

 

	NAME OF ASSIGNEE	 	ADDRESS
	 	 	 

 

	Number of shares:	 	 	 

 

	Dated:	 	 	
    Signature:
	 

 

ASSIGNEE ACKNOWLEDGMENT

 

The undersigned Assignee acknowledges
that it has reviewed the attached Warrant and by its signature below it hereby represents and warrants that it is an “accredited
investor” as defined in Rule 501(a) of Regulation D promulgated under the Securities Act of 1933, as amended, and agrees
to be bound by the terms and conditions of the Warrant as of the date hereof, including Section 7 thereof.

 

	 	Signature:	
	 	 
	 	By:	       	
	 	Its:	 	 

 

	Address:Exhibit 10.1

 

SECURITIES PURCHASE AGREEMENT

 

This Securities Purchase Agreement
(this “Agreement”) is dated as of April 26, 2021 (the “Effective Date”), among
Immunome, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature
pages hereto (each a “Purchaser” and collectively the “Purchasers”).

 

The Company and the Purchasers
are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of
the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506 of Regulation D as promulgated
by the United States Securities and Exchange Commission (the “Commission”) under the Securities Act.

 

Each Purchaser wishes to purchase,
and the Company wishes to sell, upon the terms and conditions stated in this Agreement, (i) that aggregate number of shares of Common
Stock (defined below) (the “Shares”) set forth opposite such Purchaser’s name on Exhibit A
and (ii)  a warrant in substantially the form attached hereto as Exhibit B (each, a “Warrant”
and collectively, the “Warrants”) to acquire up to that number of additional Shares set forth opposite such
Purchaser’s name on Exhibit A (the shares of Common Stock for which the Warrants are exercisable, collectively, the
 “Warrant Shares”). The Shares, the Warrants and the Warrant Shares collectively are referred to herein as the
 “Securities”.

 

In connection with the offering
and sale of the Securities, the Company has entered into an engagement letter dated April 9, 2021, (the “Engagement Letter”),
with Ladenburg Thalmann & Co. Inc. (the “Placement Agent”).

 

In consideration of the mutual
covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged,
the Company and each Purchaser, severally and not jointly, agree as follows:

 

		1.	DEFINITIONS

 

1.1          Definitions.
In addition to the terms defined elsewhere in this Agreement, the following terms have the meanings set forth in this Section 1.1:

 

“Closing”
means the closing of the purchase and sale of the Securities on the Closing Date pursuant to Section 2.1 of this Agreement.

 

“Closing Date”
means, subject to the satisfaction of the conditions to Closing set forth herein, April 28, 2021.

 

“Closing Price”
means $27.00 per share.

 

“Common Stock”
means the common stock of the Company, $0.0001 par value per share, and any other class of securities into which such securities may hereafter
be reclassified or changed into.

 

“Exchange Act”
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

     

     

    

 

“GAAP”
means U.S. generally accepted accounting principles consistently applied.

 

“Governmental
Entity” shall mean any national, federal, state, county, municipal, local or foreign government, or any political subdivision,
court, body, agency or regulatory authority thereof, and any person exercising executive, legislative, judicial, regulatory, taxing or
administrative functions of or pertaining to any of the foregoing.

 

“Investment Company
Act” means the Investment Company Act of 1940, as amended.

 

“Material Adverse
Effect” means a circumstance that (i) could reasonably be expected to have a material adverse effect on the performance
by the Company of this Agreement or the consummation of the transactions contemplated hereby or (ii) could reasonably be expected
to have a material adverse effect on the condition (financial or otherwise), business or properties of the Company; provided, however,
that “Material Adverse Effect” shall not include any event, occurrence, fact, condition or change, directly or indirectly,
arising out of or attributable to: (i) general economic or political conditions; (ii) conditions generally affecting the industry
in which the Company operates; (iii) any changes in financial or securities markets in general; (iv) acts of war (whether or
not declared), armed hostilities or terrorism, or the escalation or worsening thereof; (v) any epidemics, pandemics, disease outbreaks,
or other public health emergencies or the escalation or worsening thereof, including COVID-19; (vi) any action required or permitted
by this Agreement; (vii) any changes in applicable laws or accounting rules, including GAAP; (viii) any change in the stock
price or trading volume of the Common Stock in and of itself (however, any event, occurrence, fact or condition that results in any such
change can be taken into account for purposes of determining whether a Material Adverse Effect has occurred) or (ix) the public announcement,
pendency or completion of the transactions contemplated by this Agreement; provided, that, with respect to clauses (i)-(v) and (vii),
the Company is not disproportionately affected thereby relative to other participants in the industry or industries and geographic area
in which the Company operates.

 

“Nasdaq”
means The Nasdaq Global Select Market.

 

“Person”
means an individual, firm, corporation (including any non-profit corporation), partnership, limited liability company, joint venture,
association, trust, Governmental Entity or other entity or organization.

 

“Registration
Statement” means a registration statement or registration statements of the Company filed under the Securities Act pursuant
to Section 4 hereof.

 

“Rule 144”
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.

 

“SEC Reports”
means collectively all reports, schedules, forms, statements and other documents required to be filed by the Company under the Exchange
Act, including pursuant to Section 13(a) or 15(d) thereof, since September 30, 2020 (including the exhibits thereto
and documents incorporated by reference therein).

 

    2

     

    

 

“Short Sales”
means all “short sales” as defined in Rule 200 of Regulation SHO of the Exchange Act, but shall be deemed to not include
the location and/or reservation of borrowable shares of Common Stock.

 

“Subsidiary”
means any individual or entity the Company wholly-owns or controls, or in which the Company, directly or indirectly, owns a majority of
the voting stock or similar voting interest, in each case that would be disclosable pursuant to Item 601(b)(21) of Regulation S-K promulgated
under the Securities Act.

 

“Trading Day”
means a day on which the Common Stock is traded on a Trading Market.

 

“Trading Market”
means whichever of the New York Stock Exchange, the NYSE American, Nasdaq, the Nasdaq Global Market, the Nasdaq Capital Market or the
OTC Bulletin Board on which the Shares are listed or quoted for trading on the date in question.

 

“Transaction Documents”
means this Agreement, the Warrants and any other documents or agreements executed and delivered in connection with the transactions contemplated
hereunder.

 

“Transfer”
means to voluntarily or involuntarily sell, mortgage, gift, assign, contribute, transfer, pledge, hypothecate, participate, donate or
otherwise encumber or dispose of, directly or indirectly, in any case, whether by merger, testamentary disposition, operation of applicable
law or otherwise, or enter into a definitive agreement with respect to any of the foregoing. “Transfer” used
as a noun has a correlative meaning. Notwithstanding the foregoing, each of the following shall be deemed not to be a “Transfer”
for the purposes of this Agreement: (i) a pledge of or grant of a security interest by a holder in any Securities beneficially owned
by such holder, in connection with such holder’s bona fide indebtedness for borrowed money, to any creditor, lender or other
person performing similar functions in the ordinary course of such creditor’s, lender’s or other person’s business to
which such pledge or grant is made, (ii) the exercise by any pledgee or grantee described in the foregoing clause (i) of its
rights to foreclose on or by similar remedy otherwise acquire such shares, (iii) any transfer of any Securities by a Purchaser to
an affiliate of such Purchaser, but in the case of this clause (iii), only (1) if such affiliate agrees in writing prior to such
transfer for the express benefit of the Company (in form and substance reasonably satisfactory to the Company and with a copy thereof
to be furnished to the Company) to be bound by the terms of this Agreement and (2) if such Purchaser and such affiliate agree in
writing prior to such transfer for the express benefit of the Company (in form and substance reasonably satisfactory to the Company and
with a copy thereof to be furnished to the Company) that such affiliate shall Transfer the Securities so transferred back to such Purchaser
or another affiliate of such Purchaser in accordance with this clause at or before such time as such affiliate ceases to be an affiliate
of the Purchaser, and (iv) any transfer by a limited partner or member of equity interests in any person that holds a direct or indirect
interest in the Purchaser (or, to the extent any Securities are transferred to an affiliate of the Purchaser, in such affiliate).

 

    3

     

    

 

		2.	PURCHASE AND SALE

 

2.1          Closing.

 

(a)            At
the Closing, upon the terms set forth herein, the Company hereby agrees to issue and sell to each Purchaser, and each Purchaser agrees
to purchase from the Company, severally and not jointly, the number of Shares set forth opposite such Purchaser’s name on Exhibit A
hereto, at a purchase price per Share equal to the Closing Price.

 

(b)            At
the Closing, upon the terms set forth herein, the Company hereby agrees to issue and sell to each Purchaser, and each Purchaser agrees
to purchase from the Company, severally and not jointly, a Warrant exercisable for a number of Warrant Shares set forth opposite such
Purchaser’s name on Exhibit A hereto.

 

(c)            The
Closing shall occur at 10:00 a.m. (New York City Time) on the Closing Date remotely via the exchange of documents and signature pages or
such other time and location as the Company and Purchasers who are purchasing at least 51% in interest of the Shares based on the initial
subscription amounts hereunder shall mutually agree.

 

2.2          Deliveries;
Closing Conditions.

 

(a)            At
the Closing, the Company will deliver or cause to be delivered to each Purchaser the Shares purchased by such Purchaser, via book-entry,
registered in such Purchaser’s name. Such delivery shall be against payment of the purchase price therefor by such Purchaser by
wire transfer of immediately available funds to the Company in accordance with the Company’s written wiring instructions.

 

(b)            At
the Closing, American Stock Transfer & Trust Company, LLC (the “Warrant Agent”), on behalf of the Company,
will deliver or cause to be delivered to each Purchaser the Warrant purchased by such Purchaser registered in the Purchaser’s name.
Such delivery shall be against payment of the purchase price therefor by the Purchaser by wire transfer of immediately available funds
to the Company in accordance with the Company’s written wiring instructions.

 

(c)            The
respective obligations of the Company, on the one hand, and each Purchaser, on the other hand, hereunder in connection with the Closing
are subject to the following conditions being met:

 

(i)           the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect,
in all respects) on the Closing Date of the representations and warranties contained herein (unless made as of a specified date therein
in which case they shall be accurate as of such date) of the Company (with respect to the obligations of the Purchasers) and the Purchasers
(with respect to the obligations of the Company);

 

(ii)          all
obligations, covenants and agreements of the Company (with respect to the obligations of the Purchasers) and the Purchasers (with respect
to the obligations of the Company) required to be performed at or prior to the Closing Date shall have been performed in all material
respects;

 

(iii)         the
Purchasers shall have received a certificate of the Secretary of the Company, dated as of the Closing Date in form and substance reasonably
satisfactory to the Purchasers;

 

    4

     

    

 

(iv)          the
Purchasers shall have received a certificate signed by the Chief Executive Officer of the Company, dated as of the Closing Date in form
and substance reasonably satisfactory to the Purchasers, certifying as to the fulfillment of the conditions specified in clauses (i),
(ii), (vi), (ix) and (x) of this Section 2.2(c);

 

(v)           the
Purchasers shall have received an opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel for the Company, dated as of
the Closing Date, addressed to the Purchasers and the Placement Agent, in a form reasonably satisfactory to the Purchasers;

 

(vi)          No
Material Adverse Effect shall have occurred since the date of this Agreement;

 

(vii)        The
Company shall have obtained any and all consents, permits, approvals, registrations and waivers necessary for the consummation of the
purchase and sale of the Securities and the consummation of the other transactions contemplated by the Transaction Documents, all of which
shall be in full force and effect;

 

(viii)       The
Company shall have submitted the appropriate filings with Nasdaq for the listing and trading of the Shares and the Warrant Shares on Nasdaq,
and Nasdaq shall have raised no objection to such listing;

 

(ix)         No
judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate, including any bankruptcy court
or judge, or any order of or by any governmental authority, shall have been issued, and no action or proceeding shall have been instituted
by any governmental authority, enjoining or preventing the consummation of the transactions contemplated by the Transaction Documents;
and

 

(x)           No
stop order or suspension of trading shall have been imposed by Nasdaq, the Commission or any other governmental or regulatory body with
respect to public trading in the Common Stock on Nasdaq.

 

		3.	REPRESENTATIONS AND WARRANTIES

 

3.1          Representations
and Warranties of the Company. Assuming the accuracy of the representations and warranties of
the Purchasers set forth in Section 3.2 of this Agreement and except as set forth in the SEC Reports, which disclosures serve
to qualify these representations and warranties in their entirety, the Company represents and warrants to the Purchasers and the Placement
Agent that the statements contained in this Section 3.1 are true and correct as of the date hereof and as of the Closing Date:

 

(a)           The
Company was not and is not an Ineligible Issuer (as defined in Rule 405 under the Securities Act), without taking account of any
determination by the Commission pursuant to Rule 405 that it is not necessary that the Company be considered an Ineligible Issuer.

 

    5

     

    

 

(b)           The
Company has been duly incorporated and is validly existing as a corporation in good standing under the laws of the State of Delaware
with full corporate power and authority to own or lease, as the case may be, and to operate its properties and conduct its business,
and to execute and deliver this Agreement and the Warrants to be dated as of the Closing Date and entered into by and between the Company
and the Warrant Agent. The Company is duly qualified to do business as a foreign corporation and is in good standing under the laws of
each jurisdiction which requires such qualification except where failure to qualify would not have a Material Adverse Effect. The Company
has no Subsidiaries.

 

(c)           The
authorized, issued and outstanding shares of capital stock of the Company are as set forth in the SEC Reports (except for subsequent issuances,
if any, (A) pursuant to this Agreement, (B) pursuant to reservations, agreements or employee benefit plans referred to in the
SEC Reports or (C) pursuant to the conversion of convertible securities or exercise of options referred to in the SEC Reports). The
outstanding shares of capital stock of the Company have been duly authorized and are validly issued, fully paid and non-assessable and
have been issued in compliance with all applicable laws.

 

(d)           The
outstanding shares of Common Stock have been duly and validly authorized and issued and are fully paid and nonassessable; the Shares and
the Warrant Shares have been duly and validly authorized and, when issued and delivered to and paid for by the Purchasers pursuant to
this Agreement, will be fully paid and nonassessable and free and clear of any liens, encumbrances or other restrictions (other than those
imposed by securities laws generally or this Agreement); the holders of outstanding shares of capital stock of the Company are not entitled
to preemptive or other rights to subscribe for the Securities, except for any such rights as have been effectively waived or complied
with; and, except as set forth in Section 3.1(c) above, no options, warrants or other rights to purchase, agreements or other
obligations to issue, or rights to convert any obligations into or exchange any securities for, shares of capital stock of or ownership
interests in the Company are outstanding. The issuance of Common Stock or other securities pursuant to any provision of this Agreement
will not result in the triggering of any anti-dilution rights.

 

(e)           The
Warrants have been duly authorized by the Company and, when executed and delivered by the Company, will be valid and binding agreements
of the Company, enforceable against the Company in accordance with their terms, except as the enforcement thereof may be limited by bankruptcy,
insolvency, reorganization, moratorium or other similar laws relating to or affecting the rights and remedies of creditors or by general
equitable principles; the Warrant Shares have been duly authorized and validly reserved for issuance upon exercise of the Warrants; the
Warrant Shares, when issued and delivered upon exercise of the Warrants in accordance therewith, will be validly issued, fully paid and
nonassessable and free and clear of any liens, encumbrances or other restrictions (other than those imposed by securities laws generally,
this Agreement or the Warrants), and the issuance of the Warrant Shares is not subject to any preemptive rights, rights of first refusal
or other similar rights to subscribe for or purchase the Warrant Shares.

 

(f)            This
Agreement has been duly authorized, executed and delivered by the Company and constitutes the lawful, valid and legally binding obligation
of the Company, enforceable in accordance with its terms, except as enforceability may be limited by bankruptcy, insolvency or similar
laws affecting the rights of creditors generally and general equitable principles.

 

    6

     

    

 

(g)           No
approval, authorization, consent or order of or filing with any federal, state, local or foreign governmental or regulatory commission,
board, body, authority or agency, or of or with any self-regulatory organization or other non-governmental regulatory authority (including,
without limitation, Nasdaq) having jurisdiction over the Company, or approval of the stockholders of the Company or any other person
or entity, is required for the consummation by the Company of the transactions contemplated hereby, other than (i) any necessary
qualification under the securities or blue sky laws of the various jurisdictions in which the Securities are being offered, (ii) any
listing applications and related consents or any notices required by Nasdaq in the ordinary course of the offering of the Securities,
(iii) filings with the Commission under the Securities Act contemplated by this Agreement or (iv) filings with the Commission
on Form 8-K with respect to this Agreement.

 

(h)           The
execution, delivery and performance of this Agreement, the issuance and sale of the Securities and the consummation of the transactions
contemplated hereby by the Company will not conflict with, result in any breach or violation of or constitute a default under (nor constitute
any event which, with notice, lapse of time or both, would result in any breach or violation of, constitute a default under or give the
holder of any indebtedness (or a person acting on such holder’s behalf) the right to require the repurchase, redemption or repayment
of all or a part of such indebtedness under) (or result in the creation or imposition of a lien, charge or encumbrance on any property
or assets of the Company pursuant to) (A) the charter or bylaws of the Company, or (B) any indenture, mortgage, deed of trust,
bank loan or credit agreement or other evidence of indebtedness, or any license, lease, contract or other agreement or instrument to which
the Company is a party or by which its properties are bound or affected, or (C) any applicable federal, state, local or foreign law,
regulation or rule, or (D) any applicable rule or regulation of any self-regulatory organization or other non-governmental regulatory
authority (including, without limitation, the rules and regulations of Nasdaq), or (E) any decree, judgment or order applicable
to the Company or any of its properties, except, in the case of the foregoing clauses (B), (C), (D) and (E), for any such conflict,
breach, violation, default or event that would not have a Material Adverse Effect.

 

(i)            The
Common Stock is registered under Section 12 of the Exchange Act. The Company has filed all SEC Reports on a timely basis or has received
a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their
respective dates, the SEC Reports complied in all material respects with the requirements of the Exchange Act and, in each case, to the
rules promulgated thereunder, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material
fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light
of the circumstances under which they were made, not misleading.

 

(j)            The
financial statements and the related notes of the Company included in the SEC Reports comply in all material respects with applicable
accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing.
Such financial statements have been prepared in accordance with GAAP, except as may be otherwise specified in such financial statements
or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present
the consolidated financial position of the Company as of and for the dates thereof and the consolidated results of operations and cash
flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.

 

    7

     

    

 

(k)           No
action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or
its property is pending or, to the knowledge of the Company, threatened that would if determined adversely have a Material Adverse Effect.

 

(l)            The
Company has good and marketable title to all real properties and all other properties and assets owned by it, in each case free from liens,
encumbrances and defects, except such as would not have a Material Adverse Effect; and the Company holds any leased real or personal property
under valid and enforceable leases with no exceptions, except such as would not have a Material Adverse Effect.

 

(m)          The
Company is not in breach or violation of or in default under (nor has any event occurred which, with notice, lapse of time or both, would
result in any breach or violation of, constitute a default under or give the holder of any indebtedness (or a person acting on such holder’s
behalf) the right to require the repurchase, redemption or repayment of all or a part of such indebtedness under) (A) its charter
or bylaws, or (B) any indenture, mortgage, deed of trust, bank loan or credit agreement or other evidence of indebtedness, or any
license, lease, contract or other agreement or instrument to which it is a party or by which it or any of its properties may be bound
or affected, or (C) any applicable federal, state, local or foreign law, regulation or rule, or (D) any applicable rule or
regulation of any self-regulatory organization or other non-governmental regulatory authority (including, without limitation, the rules and
regulations of Nasdaq), or (E) any decree, judgment or order applicable to it or any of its properties, except, in the case of the
foregoing clauses (B), (C) and (D), for any such breach, violation, default or event that would not have a Material Adverse Effect
or, in the case of any indebtedness, give rise to the right of the lender to accelerate such indebtedness.

 

(n)           Deloitte &
Touche LLP, who have certified the financial statements of the Company as of December 31, 2020 and 2019 and delivered their report
with respect to the audited financial statements included in the SEC Reports, are independent public accountants with respect to the Company
within the meaning of the Securities Act and the applicable published rules and regulations thereunder.

 

(o)           The
Company possesses all licenses, certificates, permits and other authorizations issued by all applicable authorities necessary to conduct
its business, and the Company has not received any notice of proceedings relating to the revocation or modification of any such certificate,
authorization or permit which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would have a
Material Adverse Effect.

 

    8

     

    

 

(p)           Except
as would not, individually or in the aggregate, result in a Material Adverse Effect: (i) the Company is and has been in compliance
with statutes, laws, ordinances, rules and regulations applicable to it for the ownership, testing, development, manufacture, packaging,
processing, use, labeling, storage, or disposal of any product manufactured by or on behalf of the Company or out-licensed by the Company,
including without limitation, the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301, et seq., the Public Health Service Act,
42 U.S.C. § 262, similar laws of other Governmental Entities and the regulations promulgated pursuant to such laws (collectively,
 “Applicable Laws”); (ii) the Company possesses all licenses, certificates, approvals, authorizations,
permits and supplements or amendments thereto required by any such Applicable Laws and/or for the ownership of its properties or the
conduct of its business as described in the SEC Reports (collectively, “Authorizations”) and such Authorizations
are valid and in full force and effect and the Company is not in violation of any term of any such Authorizations; (iii) the Company
has not received any written notice of adverse finding, warning letter or other written correspondence or notice from the U.S. Food and
Drug Administration (“FDA”) or any other Governmental Entity alleging or asserting noncompliance with any Applicable
Laws or Authorizations; (iv) the Company has not received notice of any ongoing claim, action, suit, proceeding, hearing, enforcement,
investigation, arbitration or other action from any Governmental Entity or third party alleging that any product, operation or activity
is in violation of any Applicable Laws or Authorizations or has any knowledge that any such Governmental Entity or third party is considering
any such claim, litigation, arbitration, action, suit, investigation or proceeding, nor, to the best of the Company’s knowledge,
has there been any noncompliance with or violation of any Applicable Laws by the Company that could reasonably be expected to require
the issuance of any such written notice or result in an investigation, corrective action, or enforcement action by FDA or similar Governmental
Entity; (v) the Company has not received notice that any Governmental Entity has taken, is taking or intends to take action to limit,
suspend, modify or revoke any Authorizations or has any knowledge that any such Governmental Entity has threatened or is considering
such action; and (vi) the Company has filed, obtained, maintained or submitted all reports, documents, forms, notices, applications,
records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports,
documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete, correct and not misleading
on the date filed (or were corrected or supplemented by a subsequent submission). To the Company’s knowledge, none of the Company
or any of its directors, officers, employees or agents, has made, or caused the making of, any false statements on, or material omissions
from, any other records or documentation prepared or maintained to comply with the requirements of the FDA or any other Governmental
Entity.

 

(q)           The
pre-clinical studies and tests conducted by the Company have been and, if still pending, are being conducted in all material respects
pursuant to all Applicable Laws and Authorizations; the descriptions of the results of such pre-clinical studies and tests contained in
the SEC Reports are accurate and complete in all material respects and fairly present the data derived from such pre-clinical studies
and tests; the Company is not aware of any pre-clinical studies or tests, the results of which the Company believes reasonably call into
question the research, nonclinical study or test results; and the Company has not received any written notices or correspondence from
any Governmental Entity requiring the termination, suspension or material modification of any pre-clinical study or test conducted by
or on behalf of the Company.

 

    9

     

    

 

(r)            The
Company owns or possesses or believes it can acquire on commercially reasonable terms sufficient legal rights to all patents, patent applications,
trademarks, trademark applications, service marks, service mark applications, tradenames, copyrights, trade secrets, domain names, mask
works, information and proprietary rights and processes, similar or other intellectual property rights, subject matter of any of the foregoing,
tangible embodiments of any of the foregoing, licenses in, to and under any of the foregoing, and any and all such cases as are necessary
to the Company in the conduct of the Company’s business as now conducted and as presently proposed to be conducted (the “Company
Intellectual Property”) without, to the Company’s knowledge, any conflict with, or infringement of, the rights of
others. Except as described in the SEC Reports, (a) to the Company’s knowledge, there are no rights of third parties to any
Company Intellectual Property owned by the Company; (b) to the Company’s knowledge, there is no material infringement by third
parties of any Company Intellectual Property; (c) there is no pending, or to the Company’s knowledge, threatened action, suit,
proceeding or claim by others challenging the Company’s rights in or to any such Company Intellectual Property, and, to the Company’s
knowledge, the Company is aware of no factual basis for any such claim; and (d)  there is no pending or, to the Company’s knowledge,
threatened action, suit, proceeding or claim by others challenging the validity or scope of any such Company Intellectual Property, including
interferences, oppositions, reexaminations or government proceedings, and the Company is unaware of any facts which would form a reasonable
basis for any such claim. To the Company’s knowledge, no product or service marketed or sold (or proposed to be marketed or sold)
by the Company violates any license or infringes any intellectual property rights of any other party. Other than with respect to commercially
available software products under standard end-user object code license agreements, there are no outstanding options, licenses, agreements,
claims, encumbrances or shared ownership interests of any kind relating to the Company Intellectual Property, nor is the Company bound
by or a party to any options, licenses or agreements of any kind with respect to the patents, trademarks, service marks, trade names,
copyrights, trade secrets, licenses, information, proprietary rights and processes of any other Person. The Company has not received any
written communications alleging that the Company has violated, or by conducting its business, would violate any of the patents, trademarks,
service marks, tradenames, copyrights,

 

(s)           The
Company maintains a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed
in accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation
of financial statements in conformity with generally accepted accounting principles and to maintain accountability for assets; (iii) access
to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability
for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences.
The Company’s internal controls over financial reporting are effective and the Company is not aware of any material weakness in
its internal controls over financial reporting.

 

(t)            The
Company maintains “disclosure controls and procedures” (as such term is defined in Rule 13a-15(e) under the Exchange
Act); such disclosure controls and procedures are effective.

 

(u)           Neither
the Company nor, to the knowledge of the Company, any of its directors or officers has taken, without giving effect to activities by the
Placement Agent, any action designed to or that would constitute or that might reasonably be expected to cause or result in, under the
Exchange Act or otherwise, stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale
of the Securities.

 

(v)           There
is and has been no failure on the part of the Company, and to the knowledge of the Company, any of its directors or officers, in their
capacities as such, to comply with any provision of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated in connection
therewith (the “Sarbanes-Oxley Act”), including Section 402 relating to loans.

 

    10

     

    

 

(w)          The
Company nor, to the knowledge of the Company, any of its directors or officers is aware of or has taken any action while acting on behalf
of the Company, that would result in a violation by such Persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and
regulations thereunder (the “FCPA”), including, without limitation, making use of the mails or any means or
instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of
any money, or other property, gift, promise to give, or authorization of the giving of anything of value to any “foreign official”
(as such term is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office,
in contravention of the FCPA; and the Company and, to the knowledge of the Company, its affiliates have conducted their businesses in
compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected
to continue to ensure, continued compliance therewith.

 

(x)            The
operations of the Company is and had been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements
and the money laundering statutes and the rules and regulations thereunder and any related or similar rules, regulations or guidelines,
issued, administered or enforced by any governmental agency (collectively, the “Money Laundering Laws”); and
no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company
with respect to the Money Laundering Laws is pending or, to the Company’s knowledge, threatened.

 

(y)           Neither
the Company nor, to the knowledge of the Company, any of its directors or officers (i) is currently subject to any sanctions administered
or imposed by the United States (including any administered or enforced by the Office of Foreign Assets Control of the U.S. Treasury Department
(“OFAC”)) or (ii) will use the proceeds of this offering, or lend, contribute or otherwise make available
such proceeds to any subsidiary, joint venture partner or other Person in any manner that will result in a violation of any economic sanctions
imposed by the United States (including any administered or enforced by OFAC, the U.S. Department of State, or the Bureau of Industry
and Security of the U.S. Department of Commerce), the United Nations Security Council, the European Union, or the United Kingdom (including
sanctions administered or controlled by Her Majesty’s Treasury) (collectively, “Sanctions” and such Persons,
 “Sanction Persons”) by, or could result in the imposition of Sanctions against, any Person (including any Person
participating in the offering, whether as underwriter, advisor, investor or otherwise).

 

(z)            Neither
the Company nor, to the knowledge of the Company, any of its directors or officers, is a Person that is, or is 50% or more owned or otherwise
controlled by a Person that is: (i) the subject of any Sanctions; or (ii) located, organized or resident in a country or territory
that is, or whose government is, the subject of Sanctions that broadly prohibit dealings with that country or territory (currently, Cuba, Iran,
North Korea, Syria and the Crimea Region of the Ukraine) (collectively, “Sanctioned Countries” and each, a “Sanctioned
Country”).

 

(aa)         The
Company has not engaged in any dealings or transactions with or for the benefit of a Sanctioned Person, or with or in a Sanctioned Country,
in the preceding 3 years, nor does the Company have any plans to increase its dealings or transactions with Sanctioned Persons, or with
or in Sanctioned Countries.

 

    11

     

    

 

 

(bb)         The
Common Stock is listed on the Nasdaq. The Company has not taken any action designed to terminate the registration of the Common Stock
under the Exchange Act or delisting the Common Stock from the Nasdaq, nor has the Company received any notification that the Commission
or the Nasdaq is contemplating terminating such registration or listing. The Company is in compliance in all material respects with all
applicable listing requirements of the Nasdaq.

 

(cc)          Neither
the Company nor any of its affiliates or any other Person acting on the Company’s behalf, has engaged in any form of general solicitation
or general advertising with respect to the Securities, nor have any of such Persons made any offers or sales of any security of the Company
or any of its affiliates or solicited any offers to buy any security of the Company, or any of the Company’s or any affiliates under
circumstances that would require registration of the Securities under the Securities Act or any other securities laws or cause this offering
of Securities to be integrated with any prior offering of securities of the Company for purposes of the Securities Act in any manner that
would affect the validity of the private placement exemption under the Securities Act for the offer and sale of the Securities hereunder.

 

(dd)         No
 “bad actor” disqualifying event described in Rule 506(d)(1)(i)-(viii) of the 1933 Act (a “Disqualification
Event”) is applicable to the Company or, to the Company’s knowledge, any Company Covered Person (as defined below),
except for a Disqualification Event as to which Rule 506(d)(2)(ii–iv) or (d)(3), is applicable. “Company Covered
Person” means, with respect to the Company as an “issuer” for purposes of Rule 506 promulgated under the
1933 Act, any Person listed in the first paragraph of Rule 506(d)(1).

 

(ee)          The
Company has timely prepared and filed all material tax returns required to have been filed by it with all appropriate governmental agencies
and timely paid all taxes shown thereon or otherwise owed by it. There are no material unpaid assessments against the Company nor, to
the Company’s Knowledge, any audits by any federal, state or local taxing authority. All taxes that the Company is required to withhold
or to collect for payment have been duly withheld and collected and paid to the proper governmental entity or third party when due. There
are no tax liens pending or, to the Company’s knowledge, threatened against the Company or any of its assets or property. With the
exception of agreements or other arrangements that are not primarily related to taxes entered into in the ordinary course of business,
there are no outstanding tax sharing agreements or other such arrangements between the Company and any other corporation or entity.

 

(ff)           The
Company is not party to or bound by any collective bargaining agreements or other agreements with labor organizations. The Company has
not violated any applicable laws affecting the collective bargaining rights of employees or labor organizations, or any applicable laws
affecting employment discrimination, equal opportunity employment, or employees’ health, safety, welfare, wages and hours except
as would not have a Material Adverse Effect.

 

(gg)         Other
than the Placement Agent, no Person will have, as a result of the transactions contemplated by the Transaction Documents, any valid right,
interest or claim against or upon the Company for any commission, fee or other compensation pursuant to any agreement, arrangement or
understanding entered into by or on behalf of the Company. No Purchaser shall have any obligation or liability with respect to any fees
due to the Placement Agent by the Company.

 

    12

     

    

 

(hh)         The
Company is not required to be registered as, and immediately following the Closing will not be required to register as, an “investment
company” within the meaning of the Investment Company Act.

 

(ii)            The
Company has no other agreements or understandings (including, without limitation, side letters) with any Purchaser to purchase Shares
or Warrants on terms more favorable to such Purchaser than as set forth herein.

 

(jj)            Assuming
the accuracy of the Purchasers’ representations and warranties set forth in Section 3.2 of this Agreement, no registration
under the Securities Act is required for the offer and sale of the Securities by the Company to the Purchasers hereunder. The issuance
and sale of the Securities hereunder does not contravene the rules and regulations of Nasdaq.

 

3.2           Representations,
Warranties and Covenants of the Purchasers. Each Purchaser, for itself and for no other Purchaser,
hereby represents and warrants as of the date hereof and as of the Closing Date and covenants to the Company and the Placement Agent
as of the Closing:

 

(a)            Such
Purchaser has all requisite legal and corporate or other power and capacity and has taken all requisite corporate or other action to execute
and deliver this Agreement, to purchase the Securities and to carry out and perform all of its obligations under this Agreement; and (b) this
Agreement constitutes the legal, valid and binding obligation of such Purchaser, enforceable against such Purchaser in accordance with
its terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization or similar laws relating to or affecting the
enforcement of creditors’ rights generally and (ii) as limited by equitable principles generally.

 

(b)            At
the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on the date on which it exercises any
Warrants, it will be either: (i) an “accredited investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or
(a)(8) under the Securities Act or (ii) a “qualified institutional buyer” as defined in Rule 144A(a) under
the Securities Act. Such Purchaser is aware of the Company’s business affairs and financial condition and has had access to and
has acquired sufficient information about the Company to reach an informed and knowledgeable decision to acquire the Securities. Such
Purchaser has such business and financial experience as is required to give it the capacity to protect its own interests in connection
with the purchase of the Securities. Such Purchaser has had the opportunity to review the Company’s filings with the Commission
and has been afforded (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives
of the Company concerning the terms and conditions of the offering of the Securities and the merits and risks of investing in the Securities
and (ii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort
or expense that is necessary to make an informed investment decision with respect to the investment. The foregoing does not modify the
right of such Purchaser to rely on the representations and warranties set forth in Section 3.1.

 

    13

     

    

 

(c)            Such
Purchaser is purchasing the Securities, and upon exercise of the Warrants will acquire the Warrant Shares, for its own account, for investment
purposes only, and not with a present view to, or for, resale, distribution or fractionalization thereof, in whole or in part (within
the meaning of the Securities Act) in violation of the Securities Act. Such Purchaser understands that its acquisition of the Securities
has not been registered under the Securities Act or registered or qualified under any state securities law in reliance on specific exemptions
therefrom, which exemptions may depend upon, among other things, the bona fide nature of such Purchaser’s investment intent as expressed
herein. Such Purchaser will not, directly or indirectly, offer, sell, pledge, transfer or otherwise dispose of (or solicit any offers
to buy, purchase or otherwise acquire or take a pledge of) the Securities except in compliance with the Securities Act and the rules and
regulations promulgated thereunder.

 

(d)            Such
Purchaser has not been solicited to offer to purchase or to purchase any Securities by means of any general solicitation or advertising
within the meaning of Regulation D under the Securities Act.

 

(e)            Such
Purchaser is not a Person of the type described in Section 506(d) of Regulation D under the Securities Act that would disqualify
the Company from engaging in a transaction pursuant to Section 506 of Regulation D under the Securities Act.

 

(f)            Such
Purchaser understands that the Securities being offered and sold to it in reliance on specific exemptions from the registration requirements
of United States federal and state securities laws and that the Company is relying in part upon the truth and accuracy of, and such Purchaser’s
compliance with, the representations, warranties, agreements, acknowledgements and understandings of such Purchaser set forth herein in
order to determine the availability of such exemptions and the eligibility of such Purchaser to acquire the Securities. Such Purchaser
further understands that the Securities may not be resold or otherwise transferred except in a transaction registered under the Securities
Act or unless an exemption from such registration is available.

 

(g)           Such
Purchaser understands that nothing in this Agreement or any other materials presented to the Purchaser in connection with the purchase
and sale of the Securities constitutes legal, tax or investment advice. Such Purchaser has consulted such legal, tax and investment advisors
and made such investigations as such Purchaser, in its sole discretion, has deemed necessary or appropriate in connection with its purchase
of the Securities. Such Purchaser has independently evaluated the merits of its decision to purchase the Securities, and that (i) the
Placement Agent is acting solely as placement agent in connection with the execution, delivery and performance of this Agreement and is
not acting as an underwriter or in any other capacity and is not and shall not be construed as a fiduciary for such Purchaser, the Company
or any other person or entity in connection with the execution, delivery and performance of this Agreement, (ii) the Placement Agent
has not made and will not make any representation or warranty, whether express or implied, of any kind or character and has not provided
any advice or recommendation in connection with the execution, delivery and performance of this Agreement, (iii) the Placement Agent
will not have any responsibility with respect to (A) any representations, warranties or agreements made by any person or entity under
or in connection with the execution, delivery and performance of this Agreement, or the execution, legality, validity or enforceability
(with respect to any person) thereof, or (B) the business, affairs, financial condition, operations, properties or prospects of,
or any other matter concerning the Company, and (iv) the Placement Agent will not have any liability or obligation (including without
limitation, for or with respect to any losses, claims, damages, obligations, penalties, judgments, awards, liabilities, costs, expenses
or disbursements incurred by such Purchaser, the Company or any other person or entity), whether in contract, tort or otherwise, to such
Purchaser, or to any person claiming through it, in respect of the execution, delivery and performance of this Agreement.

 

    14

     

    

 

(h)

 

(i)           Such
Purchaser will not, prior to the effectiveness of the Resale Registration Statement (as defined below), if then prohibited by law or regulation
other than pursuant to an available exemption under the Securities Act: (i) sell, offer to sell, solicit offers to buy, dispose of,
loan, pledge or grant any right with respect to (collectively, a “Disposition”) the Securities; or (ii) engage
in any hedging or other transaction which is designed or could reasonably be expected to lead to or result in a Disposition of the Securities
by the Purchaser or an affiliate.

 

(ii)          As
of the Closing Date, such Purchaser has not directly or indirectly, nor has any Person acting on behalf of or pursuant to any understanding
with such Purchaser, engaged in any purchases or sales of the Company’s securities (including, without limitation, any Short Sales
involving the Company’s securities) since the time that such Purchaser was first contacted by the Company, the Placement Agent
or any other Person regarding the transactions contemplated hereby. Such Purchaser covenants that neither it nor any Person acting on
its behalf or pursuant to any understanding with it will engage in any purchases or sales of the Company’s securities (including,
without limitation, any Short Sales involving the Company’s securities) prior to the time that the transactions contemplated by
this Agreement are publicly disclosed.

 

(i)            [reserved]

 

(j)            Such
Purchaser will hold in confidence all information concerning this Agreement, any additional non-public information provided to such Purchaser
and the sale and issuance of the Securities until the Company has made a public announcement concerning this Agreement and the sale and
issuance of the Securities pursuant to the terms of this Agreement.

 

(k)           Purchaser
understands that no United States federal or state agency or any other government or governmental agency has passed upon or made any recommendation
or endorsement of the Securities.

 

(l)            Such
Purchaser understands that the Securities shall bear a restrictive legend in substantially the following form (and a stop transfer order
may be placed against Transfer of the Securities):

 

“THIS SECURITY HAS NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR IN ANY OTHER JURISDICTION. THIS
SECURITY MAY NOT BE OFFERED, SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THIS SECURITY UNDER APPLICABLE
SECURITIES LAWS UNLESS OFFERED, SOLD OR TRANSFERRED PURSUANT TO AN AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THOSE LAWS.

 

    15

     

    

 

(m)          Immediately
prior to the Closing, such Purchaser, together with its affiliates and any other Persons acting as a group together with such Purchaser
and any of its affiliates, beneficially owned the number of shares of Common Stock set forth on such Purchaser’s signature page attached
hereto (as such ownership is calculated pursuant to the rules of Nasdaq).

 

(n)           If
such Purchaser is not a United States person (as defined by Section 7701(a)(30) of the Code), such Purchaser hereby represents that
it has satisfied itself as to the full observance of the laws of its jurisdiction in connection with any invitation to subscribe for the
Securities or any use of this Agreement, including (a) the legal requirements within its jurisdiction for the purchase of the Securities,
(b) any foreign exchange restrictions applicable to such purchase or acquisition, (c) any government or other consents that
may need to be obtained, and (d) the income tax and other tax consequences, if any, that may be relevant to the purchase, holding,
redemption, sale or transfer of the Securities. Such Purchaser’s subscription and payment for and continued beneficial ownership
of the Securities will not violate any applicable securities or other laws of such Purchaser’s jurisdiction.

 

		4.	REGISTRATION RIGHTS

 

4.1          Definitions.
For the purpose of this Section 4:

 

(a)            the
term “Resale Registration Statement” shall mean any registration statement required to be filed by Section 4.2
below, and shall include any preliminary prospectus, final prospectus, exhibit or amendment included in or relating to such registration
statements; and

 

(b)            the
term “Registrable Shares” means the Shares and the Warrant Shares; provided, however, that a security
shall cease to be a Registrable Share upon the earliest to occur of the following: (i) a Resale Registration Statement registering
such security under the Securities Act has been declared or becomes effective and such security has been sold or otherwise transferred
by the holder thereof pursuant to and in a manner contemplated by such effective Resale Registration Statement, (ii) such security
is sold pursuant to Rule 144 under circumstances in which any legend borne by such security relating to restrictions on transferability
thereof, under the Security Act or otherwise, is removed by the Company, (iii) such security is eligible to be sold pursuant to Rule 144
without condition or restriction, including without any limitation as to volume of sales, holding period (taking into account that the
Warrant Shares are exercisable only for cash) and without the Holder complying with any method of sale requirements or notice requirements
under Rule 144, or (iv) such security shall cease to be outstanding following its issuance.

 

4.2          Registration
Procedures and Expenses. The Company shall:

 

(a)            use
its commercially reasonable efforts to file a Resale Registration Statement (the “Mandatory Registration Statement”)
with the Commission on or before the date forty-five (45) days following the Closing Date (the “Filing Date”)
to register all of the Registrable Shares on Form S-1 under the Securities Act (providing for shelf registration of such Registrable
Shares under Commission Rule 415);

 

(b)            use
its commercially reasonable efforts to cause such Mandatory Registration Statement to be declared effective within ninety (90) days following
the Filing Date (the “Effectiveness Deadline”), such efforts to include, without limiting the generality of
the foregoing, preparing and filing with the Commission any financial statements or other information that is required to be filed prior
to the effectiveness of such Mandatory Registration Statement;

 

    16

     

    

 

(c)            notwithstanding
anything contained in this Agreement to the contrary, in the event that the Commission limits the amount of Registrable Shares or otherwise
requires a reduction in the number of Registrable Shares that may be included and sold by the Purchasers in the Mandatory Registration
Statement (in each case, subject to Section 4.3), then the Company shall prepare and file (i) within twenty (20) Trading
Days of the first date or time that such excluded Registrable Shares may then be included in a Resale Registration Statement if the Commission
shall have notified the Company that certain Registrable Shares were not eligible for inclusion in the Resale Registration Statement or
(ii) in all other cases, within thirty (30) days following the date that the Company becomes aware that such additional Resale Registration
Statement is required (the “Additional Filing Date”), a Resale Registration Statement (any such Resale Registration
Statement registering such excluded Registrable Shares, an “Additional Registration Statement” and, together
with the Mandatory Registration Statement, a “Resale Registration Statement”) to register any Registrable Shares
that have been excluded (or, if applicable, the maximum number of such excluded Registrable Shares that the Company is permitted to register
for resale on such Additional Registration Statement consistent with Commission guidance), if any, from being registered on the Mandatory
Registration Statement;

 

(d)            not
less than two (2) Trading Days prior to the filing of a Resale Registration Statement or any related prospectus or any amendment
or supplement thereto, furnish via email to those Purchasers who have supplied the Company with email addresses copies of all such documents
proposed to be filed (other than any document that is incorporated or deemed to be incorporated by reference therein) for review by such
Purchasers. The Company shall reflect in each such document when so filed with the Commission such comments regarding the Purchasers and
the plan of distribution as the Purchasers may reasonably and promptly propose no later than two (2) Trading Days after the Purchasers
have been so furnished with copies of such documents as aforesaid;

 

(e)            use
its commercially reasonable efforts to cause any such Additional Registration Statement to be declared effective as promptly as practicable
following the Additional Filing Date;

 

(f)             promptly
prepare and file with the Commission such amendments and supplements to such Resale Registration Statements and the prospectus used in
connection therewith as shall be necessary to keep such Resale Registration Statements continuously effective and free from any material
misstatement or omission to state a material fact therein until termination of such obligation as provided in Section 4.7
below, subject to the Company’s right to suspend pursuant to Section 4.6;

 

(g)            furnish
to the Purchasers such number of copies of prospectuses in conformity with the requirements of the Securities Act as the Purchasers may
reasonably request, in order to facilitate the public sale or other disposition of all or any of the Registrable Shares by the Purchasers;

 

    17

     

    

 

(h)            upon
notification by the Commission that the Resale Registration Statement will not be reviewed or is not subject to further review by the
Commission, the Company shall within two (2) Trading Days following the date of such notification request acceleration of such Resale
Registration Statement (with the requested effectiveness date to be not more than two (2) Trading Days later);

 

(i)             upon
notification by the Commission that that the Resale Registration Statement has been declared effective by the Commission, the Company
shall file the final prospectus under Rule 424 of the Securities Act (“Rule 424”) within the applicable
time period prescribed by Rule 424;

 

(j)             advise
the Purchasers promptly (and in any event within one (1) Trading Day thereof):

 

(i)           of
the effectiveness of the Resale Registration Statement or any post-effective amendments thereto;

 

(ii)          of
any request by the Commission for amendments to the Resale Registration Statement or amendments to the prospectus or for additional information
relating thereto;

 

(iii)         of
the issuance by the Commission of any stop order suspending the effectiveness of the Resale Registration Statement under the Securities
Act or of the suspension by any state securities commission of the qualification of the Registrable Shares for offering or sale in any
jurisdiction, or the initiation of any proceeding for any of the preceding purposes; and

 

(iv)          of
the existence of any fact and the happening of any event that makes any statement of a material fact made in the Resale Registration Statement,
the prospectus and amendment or supplement thereto, or any document incorporated by reference therein, untrue, or that requires the making
of any additions to or changes in the Resale Registration Statement or the prospectus in order to make the statements therein not misleading;

 

(k)           cause
all Registrable Shares to be listed on each securities exchange, if any, on which equity securities by the Company are then listed; and

 

(l)            bear
all expenses in connection with the procedures in paragraphs (a) through (k) of this Section 4.2 and the registration
of the Registrable Shares on such Resale Registration Statement.

 

    18

     

    

 

4.3           Effect
of Failure to File and Obtain and Maintain Effectiveness of Registration Statement.    If
(i) the Resale Registration Statement when declared effective fails to register the Registrable Shares (a “Registration
Failure”), (ii) a Resale Registration Statement covering all of the Registrable Shares required to be covered thereby
and required to be filed by the Company pursuant to this Agreement is not filed with the SEC on or before the sixtieth (60th)
day following the Closing Date (a “Filing Failure”), (iii) a Resale Registration Statement covering all
of the Registrable Shares required to be covered thereby is not declared effective by the SEC on or before the one hundred and thirty-fifth
(135th) day following the Closing Date (or, in the event the Staff reviews and has comments to the Mandatory Registration Statement,
the one hundred and fiftieth (150th) day following the Closing Date) (an “Effectiveness Failure”)
or (iv) subject to Section 4.6, on any day after the applicable Effective Date, sales of all of the Registrable Shares required
to be included on such Resale Registration Statement cannot be made pursuant to such Resale Registration Statement or otherwise (including,
without limitation, because of the suspension of trading or any other limitation imposed by Nasdaq, a failure to keep such Resale Registration
Statement effective, a failure to disclose such information as is necessary for sales to be made pursuant to such Resale Registration
Statement, a failure to register a sufficient number of shares of Common Stock or a failure to maintain the listing of the Common Stock)
(a “Maintenance Failure”) then, as partial relief for the damages to any holder of Registrable Shares by reason
of any such delay in or reduction of its ability to sell the underlying shares of Common Stock (which remedy shall not be exclusive of
any other remedies available at law or in equity), the Company shall pay to each holder of Registrable Shares relating to such Resale
Registration Statement an amount in cash equal to one percent (1.0%) of the aggregate purchase price of such Purchaser’s Registrable
Shares then included or required to be included in such Resale Registration Statement on each of the following dates: (i) the day
of a Registration Failure, (ii) the day of a Filing Failure; (iii) the day of an Effectiveness Failure; (iv) the initial
day of a Maintenance Failure; (v) on the thirtieth day after the date of a Registration Failure and every thirtieth day thereafter
(pro rated for periods totaling less than thirty days) until such Registration Failure is cured, (vi) on the thirtieth day after
the date of a Filing Failure and every thirtieth day thereafter (pro rated for periods totaling less than thirty days) until such Filing
Failure is cured; (vii) on the thirtieth day after the date of an Effectiveness Failure and every thirtieth day thereafter (pro rated
for periods totaling less than thirty days) until such Effectiveness Failure is cured; and (viii) on the thirtieth day after the
initial date of a Maintenance Failure and every thirtieth day thereafter (pro rated for periods totaling less than thirty days) until
such Maintenance Failure is cured. The payments to which a holder shall be entitled pursuant to this Section 4.3 are referred to
herein as “Registration Delay Payments.” Registration Delay Payments shall be paid on the earlier of (I) the
dates set forth above and (II) the third (3rd) Trading Day after the event or failure giving rise to the Registration
Delay Payments is cured. Notwithstanding anything to the contrary contained herein, Registration Delay Payments shall (i) not, in
the aggregate, exceed five percent (5.0%) of the aggregate purchase price of the Registrable Shares and (ii) cease to accrue upon
ceasing to be Registrable Shares.

 

    19

     

    

 

4.4          Rule 415;
Cutback.

 

If at any time the staff of
the Commission (“Staff”) takes the position that the offering of some or all of the Registrable Shares in a
Registration Statement is not eligible to be made on a delayed or continuous basis under the provisions of Rule 415 under the Securities
Act or requires any Purchaser to be named as an “underwriter,” the Company shall (in consultation with legal counsel to the
lead Purchaser) use its commercially reasonable efforts to persuade the Commission that the offering contemplated by the Registration
Statement is a valid secondary offering and not an offering “by or on behalf of the issuer” as defined in Rule 415 and
that none of the Purchasers is an “underwriter.” In the event that, despite the Company’s commercially reasonable efforts
and compliance with the terms of this Section 4.4, the Staff refuses to alter its position, the Company shall (i) remove
from the Registration Statement such portion of the Registrable Shares (the “Cut Back Shares”) and/or (ii) agree
to such restrictions and limitations on the registration and resale of the Registrable Shares as the Staff may require to assure the Company’s
compliance with the requirements of Rule 415 (collectively, the “SEC Restrictions”); provided, however,
that the Company shall not agree to name any Purchaser as an “underwriter” in such Registration Statement without the prior
written consent of such Purchaser. Any cutback imposed on the Purchasers pursuant to this Section 4.3 shall be allocated among
the Purchasers on a pro rata basis, unless the SEC Restrictions otherwise require or provide or the Purchasers holding a majority of the
Registrable Shares otherwise agree. No liquidated damages shall accrue as to any Cut Back Shares until such date as the Company is eligible
to effect the registration of such Cut Back Shares in accordance with any SEC Restrictions (such date, the “Restriction Termination
Date” of such Cut Back Shares). From and after the Restriction Termination Date applicable to any Cut Back Shares, all of
the provisions of this Section 4 shall again be applicable to such Cut Back Shares; provided, however, that (x) the Filing
Deadline for the Registration Statement including such Cut Back Shares shall be ten (10) Trading Days after such Restriction Termination
Date, and (y) the Effectiveness Deadline with respect to such Cut Back Shares shall be the ninetieth (90th) day immediately
after the Restriction Termination Date or the 120th day if the Staff reviews such Registration Statement (but in any event
no later than three (3) Trading Days from the Staff indicating it has no further comments on such Registration Statement). Notwithstanding
anything herein to the contrary, each Purchaser acknowledges and agrees that any cutback pursuant to this Section 4.4 shall
not reduce the number of Registrable Securities (as defined in that certain Amended and Restated Investor Rights Agreement dated June 2,
2020 by and among the Company and the signatories thereto).

 

4.5           Indemnification.

 

(a)           The
Company agrees to indemnify and hold harmless each Purchaser and its affiliates, partners, members, officers, directors, agents and representatives,
and each Person, if any, who controls such Purchaser within the meaning of Section 15 of the Securities Act or Section 20 the
Exchange Act (each, a “Purchaser Party” and collectively the “Purchaser Parties”),
to the fullest extent permitted by applicable law, from and against any losses, claims, damages or liabilities (collectively, “Losses”)
to which they may become subject (under the Securities Act or otherwise) insofar as such Losses (or actions or proceedings in respect
thereof) arise out of, or are based upon, any material breach of this Agreement by the Company or any untrue statement or alleged untrue
statement of a material fact contained in the Resale Registration Statement or any omission or alleged omission to state therein a material
fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made,
not misleading or arise out of any failure by the Company to fulfill any undertaking included in the Resale Registration Statement and
the Company will, as incurred, reimburse the Purchaser Parties for any legal or other expenses reasonably incurred in investigating, defending
or preparing to defend any such action, proceeding or claim; provided, however, that the Company shall not be liable in any such
case to the extent that such Loss arises out of, or is based upon: (i) an untrue statement or omission or alleged untrue statement
or omission made in such Resale Registration Statement in reliance upon and in conformity with written information furnished to the Company
by or on behalf of such Purchaser specifically for use in preparation of the Resale Registration Statement; or (ii) any breach of
Section 4 of this Agreement by such Purchaser; provided further, however, that the Company shall not be liable to any Purchaser
Party (or any partner, member, officer, director or controlling Person of the Purchasers) to the extent that any such Loss is caused by
an untrue statement or omission or alleged untrue statement or omission made in any preliminary prospectus if either (i) (A) such
Purchaser failed to send or deliver a copy of the final prospectus with or prior to, or such Purchaser failed to confirm that a final
prospectus was deemed to be delivered prior to (in accordance with Rule 172 of the Securities Act), the delivery of written confirmation
of the sale by such Purchaser to the Person asserting the claim from which such Loss resulted and (B) the final prospectus corrected
such untrue statement or omission, (ii) (X) such untrue statement or omission is corrected in an amendment or supplement to
the prospectus and (Y) having previously been furnished by or on behalf of the Company with copies of the prospectus as so amended
or supplemented or notified by the Company that such amended or supplemented prospectus has been filed with the Commission, in accordance
with Rule 172 of the Securities Act, such Purchaser thereafter fails to deliver such prospectus as so amended or supplemented, with
or prior to or a Purchaser fails to confirm that the prospectus as so amended or supplemented was deemed to be delivered prior to (in
accordance with Rule 172 of the Securities Act), the delivery of written confirmation of the sale by such Purchaser to the Person
asserting the claim from which such Loss resulted or (iii) such Purchaser sold Registrable Shares in violation of such Purchasers’
covenants contained in Section 3.2 of this Agreement.

 

    20

     

    

 

(b)           Each
Purchaser agrees, severally and not jointly, to indemnify and hold harmless the Company and its officers, directors, affiliates, agents
and representatives and each Person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20
of the Exchange Act (each a “Company Party” and collectively the “Company Parties”),
from and against any Losses to which the Company Parties may become subject (under the Securities Act or otherwise), insofar as such Losses
(or actions or proceedings in respect thereof) arise out of, or are based upon, any material breach of Section 4 of this Agreement
by such Purchaser or untrue statement or alleged untrue statement of a material fact contained in the Resale Registration Statement (or
any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein,
in light of the circumstances under which they were made, not misleading in each case, on the effective date thereof), if, and only to
the extent, such untrue statement or omission or alleged untrue statement or omission was made in reliance upon and in conformity with
written information furnished by or on behalf of such Purchaser specifically for use in preparation of the Resale Registration Statement,
and each Purchaser, severally and not jointly, will reimburse each Company Party for any legal or other expenses reasonably incurred in
investigating, defending or preparing to defend any such action, proceeding or claim; provided, however, that in no event shall
any indemnity under this Section 4.5(b) be greater in amount than the dollar amount of the net proceeds received by such
Purchaser upon its sale of the Registrable Shares included in the Registration Statement giving rise to such indemnification obligation.

 

(c)           Promptly
after receipt by any indemnified Person of a notice of a claim or the beginning of any action in respect of which indemnity is to be sought
against an indemnifying Person pursuant to this Section 4.5, such indemnified Person shall notify the indemnifying Person
in writing of such claim or of the commencement of such action, and, subject to the provisions hereinafter stated, in case any such action
shall be brought against an indemnified Person and such indemnifying Person shall have been notified thereof, such indemnifying Person
shall be entitled to participate therein, and, to the extent that it shall wish, to assume the defense thereof, with counsel reasonably
satisfactory to such indemnified Person. After notice from the indemnifying Person to such indemnified Person of its election to assume
the defense thereof, such indemnifying Person shall not be liable to such indemnified Person for any legal expenses subsequently incurred
by such indemnified Person in connection with the defense thereof; provided, however, that if there exists or shall exist a conflict
of interest that would make it inappropriate in the reasonable judgment of the indemnified Person for the same counsel to represent both
the indemnified Person and such indemnifying Person or any affiliate or associate thereof, the indemnified Person shall be entitled to
retain its own counsel at the expense of such indemnifying Person; provided, further, that no indemnifying Person shall be responsible
for the fees and expense of more than one separate counsel for all indemnified parties. The indemnifying party shall not settle an action
without the consent of the indemnified party, which consent shall not be unreasonably withheld.

 

    21

     

    

 

(d)          If
after proper notice of a claim or the commencement of any action against the indemnified party, the indemnifying party does not choose
to participate, then the indemnified party shall assume the defense thereof and upon written notice by the indemnified party requesting
advance payment of a stated amount for its reasonable defense costs and expenses, the indemnifying party shall advance payment for such
reasonable defense costs and expenses (the “Advance Indemnification Payment”) to the indemnified party. In the
event that the indemnified party’s actual defense costs and expenses exceed the amount of the Advance Indemnification Payment, then
upon written request by the indemnified party, the indemnifying party shall reimburse the indemnified party for such difference; in the
event that the Advance Indemnification Payment exceeds the indemnified party’s actual costs and expenses, the indemnified party
shall promptly remit payment of such difference to the indemnifying party.

 

(e)          If
the indemnification provided for in this Section 4.5 is held by a court of competent jurisdiction to be unavailable to an
indemnified party with respect to any losses, claims, damages or liabilities referred to herein, the indemnifying party, in lieu of indemnifying
such indemnified party thereunder, shall to the extent permitted by applicable law contribute to the amount paid or payable by such indemnified
party as a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect the relative fault of the indemnifying
party on the one hand and of the indemnified party on the other, as well as any other relevant equitable considerations; provided, that
in no event shall any contribution by any Purchaser hereunder be greater in amount than the dollar amount of the proceeds received by
such Purchaser upon the sale of such Registrable Shares.

 

4.6          Prospectus
Suspension. Each Purchaser acknowledges that there may be times when the Company must suspend
the use of the prospectus forming a part of the Resale Registration Statement until such time as an amendment to the Resale Registration
Statement has been filed by the Company and declared effective by the Commission, or until such time as the Company has filed an appropriate
report with the Commission pursuant to the Exchange Act. Each Purchaser hereby covenants that it will not sell any Registrable Shares
pursuant to said prospectus during the period commencing at the time at which the Company gives the Purchasers notice of the suspension
of the use of said prospectus and ending at the time the Company gives the Purchasers notice that the Purchasers may thereafter effect
sales pursuant to said prospectus; provided, that such suspension periods shall in no event exceed (A) an aggregate of thirty (30)
consecutive Trading Days or (B) an aggregate of sixty (60) Trading Days during any 360-day period and that, in the good faith judgment
of the Company’s board of directors, the Company would, in the absence of such delay or suspension hereunder, be required under
state or federal securities laws to disclose any corporate development, a potentially significant transaction or event involving the Company,
or any negotiations, discussions, or proposals directly relating thereto, in either case the disclosure of which would reasonably be expected
to have a material adverse effect upon the Company or its stockholders.

 

    22 

     

    

 

4.7          Termination
of Obligations. The obligations of the Company pursuant to Section 4.2 hereof shall
cease and terminate, with respect to any Registrable Shares, upon the earlier to occur of (a) such time such Registrable Shares have
been registered and sold or transferred by the original Purchaser thereof pursuant to an effective registration statement, or (b) such
time as such Registrable Shares no longer remain Registrable Shares pursuant to Section 4.1(b) hereof.

 

4.8          Reporting
Requirements.

 

(a)          With
a view to making available the benefits of certain rules and regulations of the Commission that may at any time permit the sale of
the Securities to the public without registration or pursuant to a registration statement, the Company agrees to use commercially reasonable
efforts to:

 

(i)           make
and keep public information available, as those terms are understood and defined in Rule 144;

 

(ii)         file
with the Commission in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange
Act; and

 

(iii)        so
long as a Purchaser owns Registrable Shares, furnish to such Purchaser upon request (A) a written statement by the Company as to
whether it is in compliance with the reporting requirements of Rule 144, the Securities Act and the Exchange Act, or whether it is
qualified as a registrant whose securities may be resold pursuant to Commission Form S-3, (B) a copy of the most recent annual
or quarterly report of the Company and such other reports and documents so filed by the Company and (C) such other information as
may be reasonably requested to permit the Purchaser to sell such securities pursuant to Rule 144.

 

		5.	OTHER AGREEMENTS OF THE PARTIES

 

5.1          Integration.
Except as contemplated by the terms of this Agreement, the Company shall not sell, offer for sale or solicit offers to buy or otherwise
negotiate in respect of any security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale
of the Securities such that the rules of Nasdaq would require shareholder approval of this transaction.

 

5.2          Securities
Laws Disclosure; Publicity. The Company shall: (a) by 9:00 a.m., New York City time, on
the Trading Day immediately following the Effective Date, issue a press release disclosing the material terms of the transactions contemplated
hereby promptly following the execution and delivery hereof (the “Press Release”), and (b) by 5:30 p.m. (New
York City time) on the fourth (4th) Trading Day following the date hereof, file a Current Report on Form 8-K disclosing
the material terms of the transactions contemplated hereby (the “Form 8-K”). Upon the issuance of the Press
Release, no Purchaser shall be in possession of any material, non-public information received from the Company in connection with this
offering that is not disclosed in the Press Release.

 

5.3          Non-Public
Information. Except with respect to the material terms and conditions of the transactions contemplated
by the Transaction Documents, the Company covenants and agrees that neither it nor any other Person acting on its behalf will provide
any Purchaser or its agents or counsel with any information that the Company believes constitutes material non-public information.

 

    23 

     

    

 

5.4          Use
of Proceeds. The Company will use the proceeds from the offering for working capital and other
general corporate purposes.

 

5.5          Reservation
of Common Stock. As of the date hereof, the Company has reserved and the Company shall continue
to reserve and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of
enabling the Company to issue the Shares and the Warrant Shares pursuant to any exercise of the Warrants.

 

5.6          Disqualification
Events. The Company will notify the Purchasers and the Placement Agent in writing, prior to the
Closing Date of (i) any Disqualification Event relating to any Company Covered Person and (ii) any event that would, with the
passage of time, become a Disqualification Event relating to any Company Covered Person.

 

5.7          Form D.
The Company shall file a Form D with respect to the Securities as required under Regulation D and, to the extent the Form D
is not publicly available on the Commission’s EDGAR reporting system, will provide a copy thereof to each Purchaser promptly after
such filing.

 

5.8          Delivery.
The Company shall, upon appropriate notice from any Purchaser stating that Registrable Shares have been sold pursuant to an effective
Registration Statement, timely prepare and deliver book-entry statements representing the Securities to be delivered to a transferee pursuant
to the Registration Statement, which book-entry shares shall be free of any restrictive legends and in such denominations and registered
in such names as such Purchaser may request. Further, the Company shall cause its legal counsel or other counsel satisfactory to the transfer
agent: (i) while the Registration Statement is effective, to issue to the transfer agent a “blanket” legal opinion to
allow sales without restriction pursuant to the effective Registration Statement, and (ii) to provide all other opinions as may reasonably
be required by the transfer agent in connection with the removal of legends from the Securities (other than the removal of any affiliates
legends). A Purchaser may request that the Company remove, and the Company agrees to authorize the removal of, the legend from such Securities,
following the delivery by such Purchaser to the Company or the Company’s transfer agent of a request for legend removal: (i) following
any sale of such Securities pursuant to Rule 144, (ii) if such Securities are eligible for sale under Rule 144(b)(1), or
(iii) following the time that the Registration Statement is declared effective. If a legend removal request is made pursuant to the
foregoing, the Company will, no later than three (3) Trading Days following the delivery by a Purchaser to the Company or the Company’s
transfer agent of a request for legend removal, deliver or cause to be delivered to such Purchaser a book-entry statement representing
such Securities that is free from all restrictive legends, as requested by the Purchaser. Book-entry statements free from all restrictive
legends may be transmitted by the Company’s transfer agent to the Purchasers by crediting the account of the Purchaser’s prime
broker with the Depository Trust Company (“DTC”) as directed by such Purchaser. If a Purchaser effects a Transfer
of the Securities in accordance with this Agreement, the Company shall permit the transfer and shall promptly instruct its transfer agent
to credit shares to the applicable balance accounts at DTC in such name and in such denominations as specified by such Purchaser to effect
such transfer. Such Purchaser hereby agrees that the removal of the restrictive legend pursuant to this Section 5.8 is predicated
upon the Company’s reliance that such Purchaser will sell any such Securities pursuant to either the registration requirements of
the Securities Act, including any applicable prospectus delivery requirements, or an exemption therefrom.

 

    24 

     

    

 

		6.	MISCELLANEOUS

 

6.1          Termination.
This Agreement may be terminated by any Purchaser, as to such Purchaser’s obligations hereunder only and without any effect whatsoever
on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing has not been consummated
within ten calendar days from the Effective Date through no fault of such Purchaser; provided, however, that no such termination
will affect the right of any party to sue for any breach by the other party (or parties).

 

6.2          Fees
and Expenses. Except as expressly set forth in the Transaction Documents to the contrary, each
party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred
by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement and the other Transaction
Documents; provided, however, that the Company hereby agrees to reimburse Prentice Capital Management, LP (the “Lead Investor”)
for its reasonable and documented out-of-pocket fees (including attorneys’ fees), costs and expenses incurred in connection with
the Transaction Documents (including the Registration Statement) not to exceed $20,000, which amount may be withheld from the aggregate
purchase price per Share that is transmitted by the Lead Investor to the Company at Closing. Notwithstanding the foregoing, the Company
shall pay all transfer agent fees, stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to
the Purchasers.

 

6.3          Entire
Agreement. The Transaction Documents, together with the exhibits and schedules thereto, contain
the entire understanding of the parties with respect to the subject matter hereof and supersede all prior agreements and understandings,
oral or written, with respect to such subject matter, which the parties acknowledge have been merged into such documents, exhibits and
schedules.

 

6.4          Notices.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective upon actual receipt via mail, courier or confirmed email by the party to whom such notice is required to
be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.

 

6.5          Amendments;
Waivers. No provision of this Agreement may be waived or amended except in a written instrument
signed, in the case of an amendment, by (a) the Company and (b) Purchasers holding at least a majority of the Securities sold
in the Closing (as a single class on an as-converted to Common Stock basis) and then-held by the Purchasers or, in the case of a waiver,
by the party against whom enforcement of any such waived provision is sought. No waiver of any default with respect to any provision,
condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default
or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right
hereunder in any manner impair the exercise of any such right.

 

    25 

     

    

 

6.6          Headings.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any
of the provisions hereof.

 

6.7          Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and
their permitted successors and assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior
written consent of each Purchaser (other than by merger). The Purchasers may not assign this Agreement or any rights or obligations hereunder
without the prior written consent of the Company (other than by merger); provided, however, that a Purchaser may assign its rights pursuant
to Section 4 to a transferee of Registrable Shares who acquires at least 50.1% of such Purchaser’s Registrable Shares.
Any attempted assignment without the prior written consent required by this Section 6.7 shall be null and void.

 

6.8          Third-Party
Beneficiaries. The Placement Agent shall be the third party beneficiary of the representations
and warranties of the Company in Section 3.1 and the representations, warranties and covenants of the Purchasers in Section 3.2.
This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns and is not for
the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in this Section 6.8.

 

6.9          Governing
Law. All questions concerning the construction, validity, enforcement and interpretation of the
Transaction Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without
regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto
or its respective affiliates, directors, officers, shareholders, employees or agents) shall be commenced exclusively in the state and
federal courts sitting in the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and
federal courts sitting in the State of New York for the adjudication of any dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably
waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of
any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably
waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof
via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices
to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party
shall commence an action or proceeding to enforce any provisions of the Transaction Documents, then the prevailing party in such action
or proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred with
the investigation, preparation and prosecution of such action or proceeding.

 

6.10        Execution.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that
the parties need not sign the same counterpart. In the event that any signature on this Agreement is delivered by facsimile transmission
or by e-mail delivery (including “.pdf” format data file or any electronic signature complying with the U.S. federal ESIGN
Act of 2000, for example, www.docusign.com), such signature shall create a legally valid and binding obligation of the party executing
(or on whose behalf such signature is executed) with the same force and effect as if such signature page were an original thereof.

 

    26 

     

    

 

6.11        Severability.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.

 

6.12        Rescission
and Withdrawal Right. Notwithstanding anything to the contrary contained in (and without limiting
any similar provisions of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option
under a Transaction Document and the Company does not timely perform its related obligations within the periods therein provided, then
such Purchaser may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice,
demand or election in whole or in part without prejudice to its future actions and rights.

 

6.13        Replacement
of Securities. If any instrument evidencing any Securities is mutilated, lost, stolen or destroyed,
the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation),
or in lieu of and substitution therefor, a new instrument, but only upon receipt of evidence reasonably satisfactory to the Company of
such loss, theft or destruction and customary and reasonable indemnity or bond, if requested. The applicant for a new instrument under
such circumstances shall also pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such
replacement Securities.

 

6.14        Remedies.
The Company shall be entitled to exercise all rights provided herein or granted by law, including recovery of damages, for any breach
of the Transaction Documents.

 

6.15        Independent
Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under any
Transaction Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any
way for the performance or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained
herein or in any other Transaction Document, and no action taken by any Purchaser pursuant thereto, shall be deemed to constitute the
Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers
are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents.
Each Purchaser shall be entitled to independently protect and enforce its rights, including without limitation, the rights arising out
of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an
additional party in any proceeding for such purpose.

 

    27 

     

    

 

6.16        Construction.
The parties agree that each of them and/or their respective counsel has reviewed and had an opportunity to revise the Transaction Documents
and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party
shall not be employed in the interpretation of the Transaction Documents or any amendments hereto.

 

6.17        WAIVER
OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST
ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY,
UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.

 

6.18        Survival
and Indemnification.

 

(a)          The
representations, warranties, covenants and agreements contained in this Agreement shall survive the Closing of the transactions contemplated
by this Agreement for two (2) years.

 

(b)          The
Company agrees to indemnify and hold harmless each Purchaser and its affiliates, and their respective directors, officers, trustees, members,
managers, employees, investment advisers and agents, from and against any and all losses, claims, damages, liabilities and expenses (including
without limitation reasonable and documented attorney fees and disbursements and other documented out-of-pocket expenses reasonably incurred
in connection with investigating, preparing or defending any action, claim or proceeding, pending or threatened and the costs of enforcement
thereof) to which such Person may become subject as a result of any breach of representation, warranty, covenant or agreement made by
or to be performed on the part of the Company under the Transaction Documents, and will reimburse any such Person for all such amounts
as they are incurred by such Person; provided, that, such Person agrees to reimburse such amounts that have been finally judicially determined
to have resulted from such Person’s fraud or willful misconduct.

 

(c)          Any
Person entitled to indemnification hereunder shall (i) give prompt written notice to the indemnifying party of any claim with respect
to which it seeks indemnification and (ii) permit such indemnifying party to assume the defense of such claim with counsel reasonably
satisfactory to the indemnified party; provided that any person entitled to indemnification hereunder shall have the right to employ separate
counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of such person
unless (a) the indemnifying party has agreed in writing to pay such fees or expenses, (b) the indemnifying party shall have
failed after a reasonable period of time to assume the defense of such claim and employ counsel reasonably satisfactory to such person
or (c) in the reasonable judgment of any such Person, based upon written advice of its counsel, a material conflict of interest exists
between such Person and the indemnifying party with respect to such claims (in which case, if the Person notifies the indemnifying party
in writing that such Person elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not
have the right to assume the defense of such claim on behalf of such Person); and provided, further, that the failure of any indemnified
party to give written notice as provided herein shall not relieve the indemnifying party of its obligations hereunder, except to the extent
that such failure to give notice shall materially adversely affect the indemnifying party in the defense of any such claim or litigation.
It is understood that the indemnifying party shall not, in connection with any proceeding in the same jurisdiction, be liable for fees
or expenses of more than one separate firm of attorneys at any time for all such indemnified parties. No indemnifying party will, except
with the consent of the indemnified party, consent to entry of any judgment or enter into any settlement that does not include as an unconditional
term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect of such claim
or litigation. No indemnified party will, except with the consent of the indemnifying party, consent to entry of any judgment or enter
into any settlement.

 

[Remainder of page intentionally
left blank.]

 

    28 

     

    

 

In
Witness Whereof, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective
authorized signatories as of the date first indicated above.

 

	 	IMMUNOME, INC.
	 	 
	 	 
	 	
	 	Name:
	 	Title:
	 	 

 

	 	Address for Notice:	665
Stockton Drive, Suite 300
	 	 	Exton, Pennsylvania 19341

 

	 	Email: croche@immunome.com
	 	Attention: Chief Financial Officer
	 	 
	 	With a copy to (which shall not constitute
notice):
	 	 
	 	Attention: Sandra G. Stoneman
	 	Chief Legal Officer and General Counsel
	 	665 Stockton Drive, Suite 300
	 	Exton, PA 19341
	 	Email: sstoneman@immunome.com
	 	 
	 	and
	 	 
	 	Mintz, Levin, Cohn, Ferris, Glovsky
and Popeo, P.C.
	 	666 Third Avenue
	 	New York, NY 10017
	 	Email: krkoch@mintz.com
	 	Attention: Kenneth R. Koch

 

    29 

     

    

 

	 	PURCHASERS:
	 	 
	 	 
	 	 
	 	By:	                                                                                           
	 	Name:	 
	 	Title:	 
	 	 
	 	 
	 	Address:	           
	 	 
	 	 
	 	 
	 	 
	 	EIN:	 
	 	Contact:	 
	 	Email:	 
	 	Subscription Amount:$	             
	 	 	
	 	 	 	 

 

    30 

     

    

 

EXHIBIT A

 

CLOSING SCHEDULE

 

	Name	Shares of Common Stock to be Purchased	Warrant Shares to be Purchased
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 

 

    31 

     

    

 

EXHIBIT B

 

FORM OF WARRANT

 

    32

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}]]